Complications of arteriovenous hemodialysis access: Recognition and management  by Padberg, Frank T. et al.
Complications of arteriovenous hemodialysis
access: Recognition and management
Frank T. Padberg Jr, MD,a Keith D. Calligaro, MD,b and Anton N. Sidawy, MD, MPH,c Newark and
East Orange, NJ; Philadelphia, Pa; and Washington, DC
English language citations reporting complications of arteriovenous access for hemodialysis are critically reviewed and
discussed. Venous hypertension, arterial steal syndrome, and high-output cardiac failure occur as a result of hemody-
namic alterations potentiated by access flow. Uremic and diabetic neuropathies are common but may obfuscate
recognition of potentially correctable problems such as compression or ischemic neuropathy. Mechanical complications
include pseudoaneurysm, which may develop from a puncture hematoma, degeneration of the wall, or infection.
Dysfunctional hemostasis, hemorrhage, noninfectious fluid collections, and access-related infections are, in part,
manifestations of the adverse effects of uremia on the function of circulating hematologic elements. Impaired erythro-
poiesis is successfully managed with hormonal stimulation; perhaps, similar therapies can be devised to reverse platelet
and leukocyte dysfunction and reduce bleeding and infectious complications. ( J Vasc Surg 2008;48:55S-80S.)Management of complications associated with arterio-
venous (AV) access is an integral part of planning individual
hemoaccess procedures. These comments are formulated as
a separate but complimentary document to the Society for
Vascular Surgery Clinical Practice Guidelines for the Surgi-
cal Placement andMaintenance of Arteriovenous Hemodi-
alysis Access.
Literature citations in the English language are criti-
cally reviewed and discussed. Recent data collated from
large surveys and revised practice recommendations are
incorporated.1-3 Relevant randomized controlled trials,
meta-analyses, or systematic reviews are noted in the refer-
ence section with an asterisk [*]. However, due to the
infrequency of many of these morbidities, much of the
information is derived from clinical series. Because this is
not a systematic review, the evidence is not rigorously
classified and graded as in the Clinical Practice Guidelines.
The text outline follows that introduced in the report-
ing standards; grading of severity estimates, the extent of
treatment required, or the morbidity incurred.4 Nomencla-
ture is standardized to AV access throughout the text to
retain consistency with these standards; reference citations,
however, frequently retain terms such as fistula (autoge-
nous arteriovenous fistula) and hemoaccess (an alternate
term for AV access).
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rizing the major points discussed in each section. Consid-
eration of each complication commences with a description
of its characteristic clinical features and pathophysiology.
Presentation of recognized treatment options is followed
by current recommendations for management.
DYSFUNCTIONAL HEMOSTASIS
● Platelet dysfunction in uremia is common in patients
with end-stage renal disease (ESRD). It is often man-
ifested as bleeding into potential anatomic spaces.
X The hazard rate for bleeding in ESRD patients is
0.55 per annum
X The hazard rate increased with antiplatelet therapy
to 0.99 per annum.
● Template bleeding time is the most reliable method to
distinguish individuals at risk for bleeding because
results of other coagulation tests and the platelet count
are usually normal.
● Management of acute bleeding is best treated with
1-deamino-8-D-arginine vasopressin (DDAVP). Most
effective as a single dose, it produces a 4- to 6-hour
effect. Cryoprecipitate may play an adjunctive role, but
results have been less consistent.
● Several interventions are recommended for chronic
bleeding
X Maintenance of a hematocrit 30%
X Assurance of adequate dialysis
X Adjunctive estrogen offers a 2-week benefit.
● Persistent hemorrhage from needle holes
X Direct digital compression; adjunctive suture
X Covered stent (endograft) may be useful if skin is
intact
X For eroded skin or degenerated conduit wall, place a
jump graft.
A clinically significant bleeding tendency is a frequent
complication of uremia, and its risk is assessed by template
bleeding time. Hemorrhage into deep organs (subdural
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cardial hemorrhage) and superficial bleeding (bruising,
puncture sites, catheter entry sites) are both common. A
recent randomized clinical trial focused on pharmacologic
intervention for graft thrombosis observed a 24% incidence
of bleeding events in the placebo group 6 months.5 The
hazard rate for bleeding in the placebo group was 0.5 per
year (95% confidence interval [CI], 0.32-0.75).5 Gastroin-
testinal hemorrhage is the second leading cause of death in
acute renal failure and was the most frequent bleeding
event in the trial.5,6
Clinical features
Specifically, the vascular surgeon will encounter dys-
functional hemostasis in two common clinical situations.
The first is intraoperative, characterized by diffuse oozing
throughout the wound and prolonging both the dissection
and closure. The second is after dialysis, characterized by a
failure of hemostasis at the puncture sites in a reasonable
time. This maymanifest as external bleeding, hematoma, or
pseudoaneurysm.
In more general terms it would be advantageous if
uremic patients with a higher risk of clinically significant
bleeding could be identified before any major invasive
procedures (ie, renal biopsy, catheterization, surgery, ac-
cess placement, etc). What specific therapy could be admin-
istered before these invasive interventions?
Pathophysiology and restoration of coagulability
The increased bleeding tendency in the uremic patient
is multifactorial, but is attributed to platelet dysfunction.
Normal results on coagulation studies and normal platelet
counts with abnormal bleeding times are characteristic.7,8
Uremic patients with hemorrhagic problems often have
bleeding times of 15 to 30 minutes.7,9-12 Although the
exact mechanism has not been elucidated, clinical and basic
research has begun to unravel this clinical puzzle during
the past several decades. Defective aggregation, defective
thromboxane-A2 production, nitric oxide, fibrinogen, von
Willebrand factor (vWF), glycoprotein (GP), and the
GPIIb-IIIa complex are implicated in abnormal platelet-to-
platelet and platelet-to- vessel wall interactions.6,8,9,13
Recognition and acceptance of the template bleeding
time as the best method for identifying uremic patients at
risk for bleeding provided a reproducible end point for
clinical studies.9 Platelet aggregation studies, glomerular
filtration rate (GFR), blood urea nitrogen/creatinine level,
and bleeding times were significantly correlated, but only
the bleeding time discriminated patients affected by clinical
bleeding problems. The clinical studies described subse-
quently have used this end point to evaluate delivery of
dialysis, anemia and epoetin alfa, estrogen, cryoprecipitate,
vasopressin, and antiplatelet agents (clopidogrel). These
investigations have defined effective therapy for acute and
prolonged hemorrhage associated with uremia.
Cryoprecipitate. Results from a series of six patients
were used to advance cryoprecipitate acute therapy for
uremic bleeding.10 The patients responded to the infusionwith a shortened bleeding time or resolution of major
bleeding episodes, or both. Its mechanism of action re-
mains undefined. Potencymay vary between different prep-
arations. Cryoprecipitate is a plasma derivative containing
vWF, fibrinogen, and fibronectin.6 The typical dose is 10 U
infused during 30 minutes.10,14 The total dose is guided by
the clinical response (ie, bleeding time and cessation of
bleeding). It offers the advantage of an immediate effect;
however, its duration of action is short, the hemostatic
effects are lost 24 hours, and exposure to blood-borne
infectious disease exists. Although still widely used, subse-
quent authors have found a less consistent response to this
therapy.14 Because of these factors, cryoprecipitate is most
appropriate when the need for hemostasis is immediate.
Vasopressin. In randomized, double-blinded, placebo-
controlled trials, the effectiveness of vasopressin (DDAVP),
was confirmed by a reduction in template bleeding time
and achievement of normal periprocedural hemostasis.7,15
A synthetic analog of antidiuretic hormone, DDAVP is
hypothesized to induce the release of autologous vWF from
storage sites.16 The initial dose is 0.3 g/kg administered
intravenously with a 50 mL bolus of saline during 30
minutes. The hemostatic effect is maximal after 1 hour and
is retained for up to 4 to 6 hours.7 Repeat doses appear to
be less efficacious.17 Alternatively, it may be administered
subcutaneously (dose, 0.3 g/kg) or intranasally (dose, 2
g/kg); equivalent efficacy was demonstrated in similar
controlled clinical trials.15,18 Side effects are generally min-
imal. DDAVP provides immediate off-the-shelf treatment,
but its effect is of short duration.
Erythropoietin and restoration of red cell vol-
ume. Restoration of a hematocrit 30% effectively re-
duces bleeding time, and randomized trials have confirmed
that packed red cell transfusions or erythropoietin effec-
tively reduce clinically significant bleeding in the uremic
patient.8,11,19 An inverse relationship exists between rising
packed cell volume and decreasing bleeding time.8,19 The
effect is achieved with a hematocrit of 30% but no rela-
tionship to change was noted in platelet count.19 The
effectiveness of increased red cell mass is hypothesized to be
a rheologic effect, by directing more of the platelet ele-
ments toward the endothelial wall facilitating platelet–
vascular wall interactions.8,19 Thus, erythropoietin pro-
vides the double advantage of correcting anemia and
diminishing the risk of bleeding over the long term.
Estrogen therapy. Bleeding time in von Willebrand
disease is often corrected during pregnancy, and random-
ized, placebo-controlled trials have confirmed that estro-
gen administration shortens the bleeding time in uremic
patients, both women and men.12,20 The major advantage
of this modality is the duration of hemostatic effect of up to
14 days; the maximum reduction in bleeding time was
between 5 and 7 days, and the initial effect was evident6
hours.12 Infusions of conjugated estrogen were effective
for this time frame with a dose of 0.6 mg/kg for 4 to 5
days.12,20 Themost active agent in the conjugated estrogen
infusion was 17-estradiol.21 The transdermal application
of 17-estradiol (50 to 100 g/24 h) reduced bleeding
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cessation of active clinical bleeding in six patients with
recurrent gastrointestinal hemorrhage.22 The efficacy of
the lower dose was hypothesized to reflect the constant
steady-state levels. The mechanism of the estrogen effect
remains under investigation. Exuberant nitric oxide pro-
duction in the wall of the vascular endothelium is impli-
cated by studies relating L-arginine to defective platelet
adhesion to subendothelium in uremic patients.13,23,24
Estrogen therapy is quickly effective, and its effects are
maintained for approximately 2 weeks after a series of
doses.
Dialysis—antiplatelet and anticoagulant therapy. In
addition to the measures described previously, it is assumed
that bleeding patients have received adequate dialysis. If
not, intensification of dialysis may also be beneficial in the
bleeding patient. Heparin, used to prevent clotting in the
dialysis circuit, can also be avoided in patients with active
bleeding or elevated bleeding times.
Evidence from randomized, prospective clinical trials
shows no role for clopidogrel or warfarin as an adjunct to
patency of prosthetic or autogenous AV access. Prosthetic
access thrombosis was not reduced by 75mg of clopidogrel
plus 325 mg of acetylsalicylic acid (ASA), and the trial was
terminated prematurely because the risk of bleeding (gas-
trointestinal, hematoma, hematuria, and prolonged needle
site bleeding) doubled in the clopidogrel group. The bleed-
ing hazard rate for the treatment group was 0.99 per year
(95% CI, 0.73-1.34).5
Similarly, another randomized controlled trial with low
dose warfarin (international normalized ratio, 1.4-1.9) re-
ported no improvement in prosthetic graft function and an
increase in major bleeding events with warfarin.25 Clopi-
dogrel (75 mg) demonstrated no benefit for autogenous
access either. An improvement in patency did not translate
into an increase in autogenous AV accesses suitable for
dialysis; bleeding events did not increase, but duration of
follow-up was limited to 30 days of access use.26
Myocardial complications remain a major source of
morbidity and mortality in the patient with ESRD.27,28 As
the evidence supporting medical interventions for these
diseases grows, more renal patients are likely to be treated
with ASA, clopidogrel, warfarin, and other potent anti-
thrombotic agents for concomitant medical problems re-
lated to coronary artery disease and atrial arrhythmias.
Although these therapies are supported by level I evidence,
the subpopulation of patients with ESRD appears to have a
different level of risk for bleeding. In addition, increasing
use of percutaneous arterial and venous therapeutic inter-
ventions is accompanied by the introduction of more po-
tent agents such as GPIIb-IIIa inhibition and clopidogrel.
Intuitively, all of these therapies will create increased bleed-
ing problems in the dialysis population. Therefore, the risks
and benefits of warfarin and antiplatelet medications should
be seriously considered before prescribing them for uremic
patients.Intraoperative and postoperative bleeding diathesis
Patients scheduled for elective surgical interventions or
other common invasive procedures (ie, renal biopsy)
should be adequately evaluated and prepared for these
events. This may include a determination of the bleeding
time and appropriate intervention, as previously described.
Although heparin is not used routinely for construction of
an AV access, its use may increase intraoperative and post-
operative bleeding. Because the arterial clamp time is gen-
erally short and the arteries are fairly normal, but primarily
because of the underlying platelet abnormalities in uremic
patients, adjunctive heparin is usually not necessary for
most patients. Scheduling AV access procedures on the day
between dialyses will decrease exposure of fresh surgical
incisions to the heparin used during hemodialysis.
Recommendations. Preparation for invasive interven-
tions should include assurance of adequate dialysis, correc-
tion of anemia with hematocrit to30%, discontinuance of
medications promoting bleeding, and reasonable correc-
tion of abnormal bleeding times. If this cannot be accom-
plished with these routine procedures, estrogen should be
considered to promote correction of the bleeding time. If a
reasonable bleeding time cannot be achieved, DDAVPmay
be administered at the time of the intervention. Although
repetitive dosing may not achieve the same degree of he-
mostatic efficacy, it is probably worth repeating. If the
bleeding is still not controlled, another short-acting hemo-
static agent, cryoprecipitate, may be administered.
Needle puncture sites and high pressures on dialysis
Patients will often appear in the emergency department
after discharge from the dialysis center with persistent or
delayed access site hemorrhage. Such bleeding associated
with an AV access usually occurs due to needle puncture
during hemodialysis, but may be the result of skin erosion
overlying superficial conduits when infection is not the
cause. If limited to a needle puncture, direct digital pressure
over the site will usually achieve hemostasis. While main-
taining direct digital pressure, a bleeding time can suggest
the severity of the individual’s bleeding tendency. If the
bleeding cannot be stopped, a suture may be sufficient.
Insertion of an endograft through a separate percuta-
neous puncture site is another option for managing hema-
tomas associated with AV access conduits, especially for
rapidly expanding hematomas or when the skin is intact
over the bleeding site. This option avoids the need to make
an incision directly in the hematoma and also allows the
option of controlling the bleeding by temporarily inflating
an occluding balloon in the conduit until an endograft is
placed across the bleeding site. This option is discussed in
greater detail in the subsequent section on pseudoaneu-
rysm.
Rapidly expanding hematomas should be temporarily
controlled by continuing direct pressure to the bleeding
site for 30 to 40 minutes. If necessary, compression may be
applied to the arterial inflow part of the access. However, if
the skin has eroded over the conduit and a hematoma has
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infected AV access. Often an emergency intervention is
required. A new graft should be tunneled subcutaneously
beneath intact skin lateral or medial to the exposed site so
that the new segment of graft is covered with healthy tissue,
and the exposed segment of graft should be excised.
A well-functioning AV access is characterized by a
low-resistance venous outflow, which may be altered by
outflow stenoses or obstruction. Elevated outflow venous
pressures would predispose to access site bleeding. Thus,
although most needle puncture site bleeding can be man-
aged medically, underlying causes that should be consid-
ered include outflow obstruction, graft infection, and pseu-
doaneurysm, any of which may require more urgent
operative intervention. A duplex examination will help
define these complications.
Recommendations. Emergency onset of persistent
bleeding requires rapid acting interventions to achieve he-
mostasis and preserve the AV access. Direct digital com-
pression is effective for needle hole bleeding and may often
require an adjunctive suture. If still uncontrolled, a covered
stent may be deployed at the site. If the skin is eroded at the
bleeding site, a short jump graft through clean tissue planes
is appropriate.
INFECTION
● Diagnosis
X Usually based on local findings at the graft or access
site
X Duplex imaging is helpful in distinguishing from
noninfectious problems and in assessing the extent
of involvement
X Nonspecific manifestations (fever, leukocytosis,
bacteremia) are common presentations of catheter-
related sepsis, but unexpected sites (including aban-
doned grafts) may be identified with indium 111
(111In)-tagged leukocyte scans.
● Organisms recovered from AV access infections are
similar regardless of access
X Staphylococcus spp constitute 32% to 53%.
X Enterococci and coagulase-negative Staphylococcus
spp, 20% to 32%
X Polymicrobial infections with gram-negative bacte-
ria, 10% to 18%
X Staphylococcus and Pseudomonas spp may both be
highly destructive and likely to incur anastomotic
disruption
X Antibiotic resistance occurs early with a rising fre-
quency in dialysis-dependent patients.
● The reported incidence of infections affecting the AV
access site ranges from
X 0.56% to 5% per year for autogenous AV access
X 4% to 20% per year for prosthetic AV grafts
● Management
X Autogenous AV access infections are usually local-
ized
– May respond to antibiotics– If associated with bleeding and proximity to the
anastomosis ligation may be required.
X Prosthetic AV access grafts
– Truly localized—segmental excision/graft re-
placement
– Partial excision—appropriate for more extensive
infection not involving the anastomoses; a small
cuff of prosthetic may be left attached to the artery
avoiding the morbidity of extensive dissection in
dense scar adjacent to the neurovascular struc-
tures
– Excision-in-toto—required for removal of infec-
tion involving the anastomoses and for those with
particularly virulent organisms.
Infection is the second leading cause of failure of pros-
thetic AV accesses and autogenous AV accesses and is a
frequent complication of AV access surgery requiring hos-
pitalization. Infection ranks second to cardiovascular dis-
ease as a cause of death in hemodialysis patients.1 Infection
associated with AV access in hemodialysis patients is mul-
tifactorial. It has long been recognized that immune func-
tion is compromised in uremic and dialysis-dependent in-
dividuals. Although transcutaneous catheters are the most
frequent source of these infections, the main focus of this
document is infection at peripheral access sites.
Access infections can begin during the initial access
placement and during frequent breaches of the skin and
access conduit by dialysis needles. As a result of this inter-
relationship between skin flora and the necessity for trans-
cutaneous access to the circulation, Staphylococcus spp are
the most frequent causative organisms, with an increasing
frequency of antibiotic resistance in these and enterococcal
species. Discussion will focus on options for preservation of
the access site, recognizing that complete resolution of
infection will require sacrifice of some sites.
Clinical presentation
Diagnosis of peripheral AV access site infection is usu-
ally clinically obvious and manifested by localized findings
such as tenderness, erythema, cellulitis, induration, masses,
drainage, exposed access, and sinus tracts. These findings
may develop long after implantation, or as a consequence of
hematoma from a recent puncture or an incision from a
surgical intervention. Systemic manifestations such as fever,
bacteremia, and septicemia are more commonly associated
with catheter access; these infections are associated with
considerably greater morbidity and mortality. However,
many reports on infection in the dialysis population focused
on septicemia or bacteremia, or both, but did not distin-
guish between bloodstream infection and those related to
peripheral AV access sites. Likewise, infections originating
from the access must be distinguished from other sources
such as pneumonia, osteomyelitis, septic arthritis, and en-
docarditis.29
The mortality rate at the commencement of dialysis is
12%; this increases to 15% during the third month after the
first dialysis. Infection-related mortality rates during this
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years.1 According to a survey sponsored by the Centers for
Disease Control and Prevention (CDC), an average of 3.2%
of patients per month (range, 0.31%-3.98%) at United
States dialysis centers will experience a vascular access–
related infection; fully 55% were associated with bacter-
emia.30
The prosthetic AV access conduit is intentionally
placed in a superficial tunnel; thus, the distinction between
subcutaneous inflammation and graft involvement may be
difficult because erythema, tenderness, and indurationmay be
present for a variable length of time postoperatively. Accurate
determination of the extent of graft infection is critical to
successful management but may not be clarified until opera-
tive exploration. It is particularly important to recognize in-
fection involving the arterial anastomosis.
Pathophysiology and diagnostic evaluation
Patients with ESRD are prone to infection from uremia-
induced immunologic dysfunction, including impaired
lymphocyte-mediated cellular immunity, neutrophil che-
motaxis, phagocytosis, bacterial killing, and metabolic
function.31-36 Recent data suggest that resistance to plate-
let microbicidal protein is a permissive factor in the devel-
opment of infection with intravascular devices.37 Other
mechanisms of altered polymorphonuclear neutrophil
function include malnutrition, iron overload, increased in-
tracellular calcium, the dialysis treatment, and circulating
plasma factors.31 Although septicemia may originate from
many different sites (pneumonia, foot sepsis, urinary tract
infection, decubitus ulcers, endocarditis), an established
intravascular focus is usually responsible for satellite infec-
tion in the spine, septic joints, endarteritis, or endocard-
itis.34,38
Bloodstream infections: bacteremia and septicemia. An
increasing international body of data implicates catheter
access as the leading source of these bloodstream infec-
tions. Epidemiology of Bacteremia in Dialysis Patients
(EPIBACDIAL), a prospective, French multicenter cohort
study, compared bloodstream infections with peripheral
site infections and found a relative risk of 7.6 between
catheter and autogenous AV access; 81% of their patients
were dialyzed through an autogenous AV access.38 In the
United Kingdom, tunneled catheters had a 5.43 hazard
ratio for bacteremia (95% CI, 2.67-11.0, P  .001) com-
pared with autogenous AV access, and the hazard ratio was
3.39 (95% CI, 1.67-6.87, P  .001) when analyzed for
mortality; however, the number of grafts at this center was
too low for reasonable comparison.39
An integrated nephrology network in the western
United States conducted a prospective cohort study of
access-related infections; 62% of the encounters were with
prosthetic AV access. There was no significant difference
between autogenous and prosthetic AV access, but tun-
neled catheters, accounting for 20% of the encounters, had
a relative risk of 33.0 (95% CI, 10.5-103.8, P .0001) for
bacteremia and sepsis.40Tokars et al,30 from the CDC, recruited 109 centers in
30 states to form the Dialysis Surveillance Network in the
United States. Overall, there were 3.22 access-related in-
fections per month, of which 1.78 per month were bacte-
remias. As expected, the rate ratios for access-related bac-
teremia were less with autogenous AV access (0.48 [95%
CI, 0.35-0.65]), or prosthetic graft (1.0 [reference]) than
with a cuffed catheter (9.2 [95% CI, 7.7-10.8]). Indepen-
dent risk factors for access-related infection were catheter
access, low albumin, urea reduction ratio, and hospitaliza-
tion 90 days.
A unique contribution fromTokars’ investigation dem-
onstrated the magnitude of the difference in infection rates
between dialysis centers. These findings were consistent
with a pilot study suggesting that an increase in peripheral
site-related bacteremia was associated with an inner city
location.41 Although personal hygiene as a risk factor was
implicated by a previous study,42 this was only significant in
the univariate analysis of the pilot data.41 Mean access-
related infection events per month in the different centers
ranged from 0.31 to 3.98. The infection rate was signifi-
cantly reduced in 11 centers and was significantly increased
in 14 centers.30
Despite intensive programs to curb their use, 81% of
United States ESRD patients initiate dialysis with a cathe-
ter, and only 26% have an autogenous or prosthetic AV
access already in place. Although the most likely reason for
the increase in 1-year mortality was attributed to catheter
access and infection, overzealous treatment of anemia, in-
travenous iron, and intravenous vitamin D were also asso-
ciated with this increase.1
Adjuncts to clinical diagnosis: duplex imaging, nu-
clear medicine. Because the peripheral AV access is punc-
tured thrice weekly for maintenance hemodialysis, bleeding
and hematoma will occasionally complicate this process.
Surgical incisions and recently implanted prosthetic grafts
require several weeks to heal and become fully incorporated
into the surrounding tissues. Failure of this process may
result in seromas or perigraft fluid collections. Appropriate
perioperative antibiotic prophylaxis is the best preventive
measure during this critical early implantation phase.
Duplex ultrasound imaging may be helpful in resolving
the diagnosis. Perigraft fluid collections can be distin-
guished from pseudoaneurysm. Serial examinations may be
performed to monitor the progress or resolution of hema-
tomas and fluid collections. A reasonable prediction of the
extent of a perigraft fluid collection using duplex ultra-
sound imaging has direct bearing on preoperative planning
when infection is actually present. The functional status of
the access becomes important when considering proce-
dures to salvage an access with localized infection.
Occasionally, the diagnosis of infection and the clinical
findings are nonspecific, such as patients with positive
blood cultures, leukocytosis, or fever. Localization of pros-
thetic graft infection with 111In-tagged leukocyte scanning
is highly sensitive, but not necessarily specific, because any
inflammatory response may suggest infection.43-45 How-
ever, false-negative reports may be relatively frequent, the
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111In scans with the functional access punctured thrice
weekly is unknown.
Organisms. Subcutaneous prosthetic AV accesses ac-
count for most peripheral access site infections, with a small
percentage contributed by autogenous AV access. Because
they have the lowest incidence of infection, autogenous AV
access is often used as the reference value for estimates of
relative risk.38,39,40
Most peripheral access site infections are caused by
gram-positive cocci. S aureus accounts for 50% to 70% of
these infections.30,43,46-48 Coagulase-negative staphylo-
cocci are usually second in frequency, followed by polymi-
crobial infections with multiple gram-negative bacteria. S
aureus is more common with prosthetic or autogenous AV
accesses (54%) than with bacteremias (32%).30 In the sur-
veillance study by Tokars et al,30 only 12% of bacteremic
isolates originated from peripheral access infections: 53%
S aureus, 20% coagulase-negative staphylococci, 10% other
gram-positive organisms, 10% gram-negative rods, and
15% other organisms. The majority (66%) of bacteremic
isolates were from patients with catheters: 32% S aureus,
32% coagulase-negative staphylococci, 18% gram-negative
rods, and 12% other gram-positive organisms (predomi-
nantly Enterococcus spp). The remaining 23% consisted of
19% secondary bacteremias (wounds unrelated to the ac-
cess, urine, osteomyelitis, pneumonia) and 4% contami-
nants. Fungal infection with a prosthetic or autogenous AV
access was unusual.30
Antibiotic resistant organisms are common: S aureus,
38%; coagulase-negative staphylococci, 6.5%; and Entero-
coccus spp, 4.6%.30,37,39 Arterial dissolution with aneurysm
formation is more frequently encountered in infections
with virulent organisms such as Pseudomonas or S au-
reus.49-51 Grafts with convincing clinical findings of inf-
ection that produce no growth with standard culture
techniquesmay occur as frequently as 25%.47,48 This incon-
sistency is often attributed to preoperative antibiotic ad-
ministration. Enhanced microbiologic techniques with
gentle sonication of explanted prosthetic AV access may
improve the yield, particularly for late AV access graft
infections and organisms with a high adherence to graft
material.47
The chronically thrombosed prosthetic or autogenous
AV access may be considered a source of otherwise unex-
plained systemic infection. Removal of these prosthetic
grafts can require an extensive dissection and may be asso-
ciated with nerve injury, bleeding, and significant patient
discomfort. However, Ayus and Sheikh-Hamad43 identi-
fied subclinical infection in a number of otherwise asymp-
tomatic dialysis patients with 111In-tagged leukocyte scans.
The threshold for evaluating these grafts for clinical
investigation has been lowered, but there are no clear
guidelines for management of the otherwise asymptomatic
patient. This limited experience indicates that in patients
with no other identifiable source of infection, it may be
prudent to remove the nonfunctional 111In-positive graft.Management and treatment options
The choice of conduit has a profound effect on the
incidence and treatment of AV access infection. Access site
infections should be reported as early (30 days) or late
(30 days), culture-positive or culture-negative, and iden-
tify the site of the infection, whether para-anastomotic,
mid-AV access, or outflow veins.4
Surgical intervention is usually required for true AV
access infections. The recommended therapy for these
complications depends on the (1) extent of infection, (2)
type of AV access conduit (autogenous vs prosthetic), (3)
bacterial etiology, (4) functional status of the AV access
(patent or occluded), and (5) type of presentation (bleed-
ing, purulent drainage, cellulitis, fever of unknown origin).
Management includes total, subtotal, or segmental AV
access excision or (rarely) complete AV access preservation.
Autogenous. The low incidence of infection with the
autogenous AV access is one of its major clinical advan-
tages. Autogenous AV access infections are usually related
to puncture site hematoma, pseudoaneurysm, or incisional
complications. The reported frequency is 0.56% to
4.5%.40,52-54 Because the rate of infection for the autoge-
nous AV access is so low, it is frequently assigned the
reference value of 1.0 for investigations assessing compar-
ative risk.38-40 Broad-spectrum antibiotics should be ad-
ministered if AV access infection is suspected, such as
-lactam antibiotics or vancomycin and gentamicin. Intact
autogenous AV access infections have occasionally resolved
with 4 to 6 weeks of parenteral antibiotics.55 Infections that
originate at a puncture site should be observed for subse-
quent reinfection.56
Local manifestations of cellulitis, abscess, pseudoaneu-
rysm, or hematoma are the usual findings with infection
involving autogenous AV access. However, thrombus
within the aneurysmal AV access may become a source of
endarteritis.57 Owing to its infrequent occurrence, there is
a paucity of published experience.46,52-57 The combined
presence of bleeding, proximity to an anastomosis, and
local site infection is more likely to result in sacrifice of the
access.46,53However, if not localized at an anastomosis, the
infected area may be ligated and a new anastomosis con-
structed in a clean field.46,56
Prosthetic grafts. Prosthetic grafts, predominantly
polytetrafluoroethylene (PTFE), have until recently ac-
counted for most AV access sites in the United States. With
the success of the National Kidney Foundation Kidney
Disease Outcomes Quality Initiative (KDOQI) and Fistula
First initiatives, autogenous access is replacing prosthetic
grafts in United States practice.58 The advantages of the
prosthetic graft include ready availability of a standard size
conduit that is easily punctured and has a short maturation
time. In addition to infection, disadvantages of prosthetic
grafts include a short life expectancy and fibrointimal hy-
perplasia. A recent randomized controlled trial comparing
an autogenous brachiobasilic AV access with a prosthetic
forearm loop configuration found in favor of the autoge-
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and complication rate.59
The reported incidence of infection with prosthetic AV
access ranges from 3.5% to 19%.46,48,52-55,59 If infection
truly involves the AV access conduit and is not simply
cellulitis, systemic antibiotics alone are usually inadequate
as the sole treatment.
Total or subtotal AV access excision should be performed
for infected conduits when the (1) access is causing septi-
cemia, (2) access is occluded, (3) infection is due to Pseudo-
monas spp or other aggressive bacteria, or (4) the entire AV
access is involved with infection as manifested by pus or
fluid surrounding the entire conduit or when the conduit is
completely unincorporated. Occasionally, total or subtotal
AV access excision is necessary in patients with persistent or
recurrent bacteremia even when there is no overt evidence
of access infection.
The venous end of the prosthetic graft should be re-
moved and the vein oversewn or ligated. If the arterial
anastomosis is intact, a small cuff of the AV access graft can
be oversewn to maintain patency of the underlying ar-
tery.48,60 If the arterial anastomosis is involved, or infection
recurs in the retained cuff, débridement of the infected
arterial wall is needed. Reconstruction with autogenous
patch angioplasty has had inconsistent success, and arterial
ligation or bypass through clean tissue planes may be re-
quired.46,52When required, radial or distal brachial ligation
(below the profunda brachii) is well tolerated in the pres-
ence of functioning collateral circulation.52
Segmental access excision with placement of a new jump
graft through a sterile field should be considered if infection
is localized to one part of the conduit. In more than half of
infected prosthetic AV accesses, infection is confined to a
focal segment of the graft 55 An infected, disrupted anasto-
mosis must be managed by excision of at least that segment
of the AV access. To perform partial AV access excision with
a jump graft, the infected site should first be covered and
isolated with sterile adhesive dressing after the arm is pre-
pared. Through separate, clean incisions proximal and dis-
tal to the infected area, sterile segments of the patent AV
access or native arteries are exposed. A short new bypass
graft is tunneled subcutaneously through a sterile field and
anastomosed to the divided ends of the original AV access
or to an uninvolved artery, depending on the extent of the
infection. Once the new incisions are closed primarily and
isolated with sterile adhesive dressings, the infected seg-
ment is excised through a separate incision.
Complete AV access preservation may be attempted
when a small segment of the conduit is involved. However,
this strategy using delayed secondary-intention wound
healing is usually less successful than for lower extremity
arterial bypasses because an AV access is usually very super-
ficial and located immediately under the skin. Placement of
a muscle flap can be considered, but again, this is usually
not possible because of the superficial position of the bypass
and unsuitability of adjacent muscles.Results and recommendations
Infected prosthetic AV accesses treated by total, subto-
tal, or partial graft excision (51 graft infections in 45
patients) were managed using the above strategies at Penn-
sylvania Hospital.48 Thirteen patients underwent total graft
excision in the presence of systemic sepsis. Fifteen patients
with infection involving a patent graft without sepsis re-
quired subtotal graft excision involving a small, oversewn
cuff of prosthetic graft adjacent to the arterial anastomosis.
Twenty-three patients with localized infection in one seg-
ment of the graft and absence of fluid around the remaining
uninfected portion of the graft as documented by preoper-
ative ultrasound and intraoperative findings underwent
segmental graft excision with placement of a new jump
graft through a sterile field. None of the 45 patients died.
Palder et al55 reported a similar experience in 22 grafts.
The wounds healed in all patients treated with total or
subtotal graft excision, although patients required insertion
of a temporary dialysis catheter and placement of a new
permanent AV access at a different site at a later time. In
patients treated with segmental graft excision, graft patency
was maintained and wound healing was achieved in 74%,
whereas failures ultimately required total graft excision.
Schwab et al61 reported a 94% success rate when 17
patients were treated with segmental graft excision. Preser-
vation of a significant part of the incorporated graft was
possible in many of these patients, and the graft was used
for immediate dialysis, avoiding the need for temporary
catheters or new permanent dialysis access. These results
suggest that subtotal and segmental graft excision can be
safely used in selected patients with infected prosthetic AV
grafts.
NONINFECTIOUS FLUID COLLECTIONS
● Most of these complications may be managed with
limited intervention, but each has the potential to
result in loss of access.
● Hematoma
X Incidence is 0.073 to 0.2 per patient-year without
regard to type of access.
● Seroma
X Incidence ranges from 0.48% to 4.2%
X Essentially a complication of prosthetic access
X There is no clearly preferable choice of management
among aspiration, closed suction drainage, graft
replacement, or capsule débridement.
● Lymphocele-lymphorrhea
X Minimal data are available about lymphatic compli-
cations of access
X Surgical exploration may identify the leaking lym-
phatic(s)
X If no cause of venous obstruction is found for
lymphedema, management largely consists of care-
ful control of symptomatic swelling with compre-
ssion.
Localized noninfectious fluid collections representing
hematomas, seromas, lymphoceles, or lymphedema will
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presentation may be similar, but it is critically important to
distinguish these from infection, abscess, or pseudoaneu-
rysm because the implications for management vary signif-
icantly.
Although recognized as a noninfectious problem ini-
tially, each of these collections can be secondarily compli-
cated by infection. Duplex scan examination is helpful for
both diagnosis and guidance for aspiration of the fluid.
Hematoma
Identification of a hematoma is usually obvious if the
immediate history is known. Bleeding from needle punc-
ture sites may be prolonged after a dialysis session. In
particular with a newly matured autogenous AV access,
posterior wall puncture may not be well controlled, leading
to hematoma and diffuse infiltration of tissue planes. This
low-frequency complication may occur with any peripheral
access configuration. The incidence ranges from 0.073 to
0.2 per patient-year in recent studies.59,62
Clinically significant bleeding is a frequent complica-
tion of uremia. This section will focus on the mechanical
aspects of contained, nonexpanding hematomas because
medical corrective measures and the approach to active
surgical bleeding were discussed previously.
Hematomas associated with AV accesses usually arise
from needle punctures during hemodialysis. In the absence
of infection, a persisting nonexpanding intraluminal com-
munication, or pseudoaneurysm, the bleeding will usually
stop and the extravasated blood will diffuse into local tissue
planes. These are usually reabsorbed and can be observed
through the ecchymotic stage until they have resolved.
Seroma
Seromas are sterile fluid collections that can develop
around prosthetic AV grafts and almost never involve au-
togenous AV accesses. These collections occur due to tran-
sudation of sterile serum-like fluid and are confined within
a nonsecretory fibrous pseudomembrane surrounding the
graft.63 Although the etiology is unclear, they have been
reported with Dacron, bovine, and PTFE prostheses.64,65
Seromas usually appear within the first month after place-
ment, are often close to the arterial anastomosis, and may
simulate a pseudoaneurysm.66
Ultrasound-guided needle aspiration of the fluid yield-
ing serous or gelatinous material is consistent with a seroma
and can be both diagnostic and possibly therapeutic. This
strategy facilitates diagnosis by submitting the fluid for
white blood cells and bacteria evaluation, which may sug-
gest an infectious or lymphatic etiology. Treatment options
include serial aspirations, wrapping the graft with microfi-
brillar collagen (Avitene, Davol/Bard, Cranston, RI), sur-
gical excision of the entire seroma with débridement of
inflammatory tissue from around the graft while leaving the
graft in situ, and replacing the graft with a conduit different
from the original one.64 Aspiration may be as successful as
observation alone (about 68%) but was associated with
infection or graft thrombosis in 8% of cases in one series.65Drainage of the seroma and excision of the pseudomem-
brane was associated with a 72% success rate, but infection
or thrombosis occurred in 12% of cases in a different
series.63 In situ graft replacement resulted in the highest
success rate (92%) in a series of 279 cases compiled from a
survey of American vascular surgeons.65 The most worri-
some concern about this strategy is whether the fluid is
infected, but the clinical presentation, Gram stains, and
cultures usually help determine the true etiology of the
fluid. Although recognized as a noninfectious problem
initially, repetitive interventions can still be secondarily
complicated by infection and loss of the access.
Lymphatic
A lymphocele, lymphorrhea, or lymphedema can occur
as a result of disrupted small lymphatics during dissection to
expose the arterial or venous structures or during tunneling
through the subcutaneous tissue. Lymphatics and lymph
nodes concentrated along the medial aspect of the extrem-
ity may be disrupted or become inflamed as a result of
surgery. Accurate distinction between lymphocele and
other localized collections may be difficult, but the man-
agement is similar to that for perigraft seroma. Fortunately,
this is a very infrequent complication of hemoaccess proce-
dures.
Lymphorrhea or a discrete lymphocele in an extremity
is characterized by clear fluid. A small, nonenlarging lym-
phocele may resolve with simple observation. External lym-
phatic drainage and lymphoceles in communication with
the access will usually respond to surgical exploration.
Extrapolating from the experience with arterial reconstruc-
tion, identification and obliteration of leaking lymphatic
tissue may be the key.67 Diffuse lymphedema of the ex-
tremity is treated nonoperatively. Generally, the edema will
resolve after a few days or weeks with elevation. Manage-
ment of recalcitrant edema may require localized compres-
sion of the extremity with careful attention to the access
site. Each of the noninfectious fluid accumulations is dis-
tinct from infection, which must be excluded before pro-
ceeding to treat these. Unfortunately, intervention for cor-
rection of the problem is also a risk factor for introducing
infection.
PSEUDOANEURYSM
● Pseudoaneurysm
X Most are complications of prosthetic grafts
X Incidence is estimated at 2% to 10% during the
functional life of a graft
X Will also complicate autogenous access, but less
frequently.
● Location often determines management: puncture site
vs anastomosis.
● Puncture site pseudoaneurysm
X A small, stable pseudoaneurysm may resolve with
observation
X Expanding pseudoaneurysm requires treatment– If due to infection, treat as an infected site
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e Suture repair
e Segmental replacement
e Endovascular by deployment of a covered stent
graft.
● Anastomotic pseudoaneurysm generally requires inter-
vention.
● Diffuse aneurysmal dilation of a long-standing AVF
rarely needs intervention.
A localized mass is the primary manifestation of a
pseudoaneurysm, which may occur at the anastomosis or
along the course of the access. Diagnosis is confirmed by
duplex examination localizing the neck of the aneurysm.
Perianeurysmal inflammation or fluid collections suggest
infection. Sterile pseudoaneurysms usually occur after nee-
dle puncture, whereas anastomotic pseudoaneurysms are
more likely to have an infectious etiology.
Clinical features and pathophysiology
An incidence of access-related pseudoaneurysms has
been reported to be 0.049 to 0.1 per patient-year reported
from two Dutch randomized trials, which probably under-
estimates this problem because it was limited to a single
year of observation after construction of a new access.59,62
Previous case series with longer observation periods report
pseudoaneurysms in 2% to 10% of PTFE grafts,53,55,68
which is a higher incidence than in autogenous ac-
cess.50,53,62 Pseudoaneurysm tends to occur in that portion
of the access closest to the arterial inflow, and it has been
suggested that reductions of intragraft pressures or venous
outflow obstruction, or both, contribute to their forma-
tion.69 Although not a pseudoaneurysm, diffuse aneurys-
mal dilation and elongation of the autogenous AV access is
also described here because the two are often confused
clinically.
Management and treatment options
Management of an AV access pseudoaneurysm de-
pends on the etiology (puncture site vs anastomotic vs
diffuse dilation, sterile vs infectious) and the location (en-
dovascular vs surgical management) of the lesion.
Puncture site pseudoaneurysm. A small puncture
site pseudoaneurysm can often be observed andmay resolve
without further treatment; however, surgical intervention
may be necessary if it is enlarging or acutely expanding.
Diffuse involvement of a prosthetic conduit may herald
a loss of integrity in the anterior wall structure of the graft.
Depending upon the extent of this destruction, segmental
resection may be used with anastomosis to the residual
arterial and venous ends of the graft as inflow and outflow
sites.50,53,55
A covered stent offers an endovascular alternative to
surgical management.68-70 Deployment of a short covered
stent (endograft) will control an actively communicating
puncture site and is also valuable for lesions that are difficult
to repair with open surgical exposure, such as sites that have
undergone repeated punctures, sites with extensive scarringdue to past surgery or repeated punctures, or sites located
near the axilla. Vesely69 notes that this represents an off-
label indication and reported a 6-month patency of 20% in
11 PTFE-covered stents. Dialysis through the area of the
covered graft should be avoided for some time because the
aneurysm may recur and the supporting covered stent may
also be disrupted. Also, similar to endovascular therapy for
abdominal aortic aneurysm, the aneurysm sac may not
regress rapidly if filled with organized thrombus.68-70
Anastomotic pseudoaneurysm. Anastomotic disrup-
tion resulting in pseudoaneurysm should always be man-
aged by surgical or endovascular revision. The most com-
mon cause of an anastomotic pseudoaneurysm is infection,
and it should be treated as outlined previously.
Although it is possible for sutures to erode through the
arterial wall because of arterial wall degeneration, undue
tension, or inadequate depth of suture bites, these causes
are uncommon in the AV access population. If infection is
not the cause, oversewing a small anastomotic defect may
suffice. However, a patch or short jump graft may need to
be placed from the original graft to a new segment of
uninvolved artery.50,55
Diffuse enlargement of an autogenous AV access.
Aneurysmal dilation and tortuosity is a unique feature that
may develop in an autogenous AVF that has functioned for
many years. Because these develop with expansion of the
autogenous AV access lumen, all layers of the access walls
are dilated. Although not a pseudoaneurysm, these are
often mislabeled as such. These AV accesses function ex-
tremely well for the purpose of hemodialysis as long as the
lumen is not filled with layered thrombus and the cutane-
ous envelope remains intact. An aneurysmal AV access may
raise concern from the staff, but there is no reason to
intervene as long as the AV access is functioning well for
dialysis and the dilatation is not steadily and rapidly
enlarging.
The usual indication for intervention is compromise of
the overlying skin. In addition, obstructive kinks and in-
traluminal thrombus may compromise dialysis exchanges.
Constructing a more proximal AV access using the arteri-
alized vein end-to-end anastomosis after excision of redun-
dant aneurysm, or a prosthetic graft, can restore a func-
tional access.
VENOUS HYPERTENSION
● Proximal, large vein obstruction is increasingly com-
mon (peripherally inserted central catheters [PICCs],
defibrillators, pacemakers, and both permanent and
temporary dialysis catheters).
● Subclinical venous obstruction is often unmasked by
the increased flow of a well functioning AV access.
● Significance:
X Unilateral symptoms may reflect regional or central
vein obstruction
X Superior vena cava obstruction may eliminate con-sideration of both upper extremities
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cal symptoms of venous insufficiency.
● Central venous stenosis/obstruction:
X Angioplasty alone is most appropriate for subclavian
sites due to the potential for extrinsic compression
X Angioplasty with or without stent is preferable as
initial therapy.
X Surgical bypass is more durable but incurs consider-
ably greater risk.
● Localized venous insufficiency from retrograde venous
flow patterns may be resolved by:
X Ligation of veins with retrograde flow
X Correction of localized outflow obstruction.
● Regional outflow obstruction
X Fibrointimal hyperplasia at the outflow anastomosis
or outflow vein is the most common problem with
prosthetic AV access.
X No clear treatment preference for elective treatment
of 50% stenosis between angioplasty, stent, and
observation based upon several randomized, pro-
spective trials
X Bypass of localized obstruction for well-functioning
AV access sites:
– Cephalic arch stenosis is especially troublesome
– Outflow transposition retains a functional site.
Symptoms of V-HTN were recognized in its complete
clinical form within a decade of the initial reports advocat-
ing AV access for hemodialysis.71-73 The most common
manifestation of V-HTN is regional edema, although other
typical signs and symptoms such as pigmentation, indura-
tion, dermatosclerosis, and ulceration may be produced.
The pathophysiology is straightforward but is frequently
misunderstood or misdiagnosed. The essential concept
pairs a functioning AV access, which increases arterial blood
flow to an extremity, with an obstruction to venous out-
flow.
Pre-existing venous obstruction may not be readily
recognized. To produce V-HTN, the obstruction must be
located close enough to the AV access outflow to permit
filling of branch veins. If there were no intervening
branches between the access and the obstruction, throm-
bosis would occur; thus, obstruction may produce a local-
ized V-HTN or affect an entire extremity. Central vein
obstruction may affect one or both extremities. Normal
blood flows are generally accommodated by the develop-
ment of extensive collateral drainage beds. A slightly differ-
ent variant is seen with the valvular incompetence that
occurs with the less frequently constructed side-to-side
autogenous AV access; dilation of the vein may render the
valves in the branches incompetent, permitting high-
volume retrograde flow to be redirected distally. Progres-
sive intimal hyperplastic stenosis in an outflow vein may
produce similar volume redirection.
Clinical features of V-HTN
Liberal use of central venous catheters, and the result-
ing venous obstruction, makes this the most commoncomplication limiting venous access options in the upper
extremities.2,3 In the absence of AV access flow, central
vein stenosis or obstruction is often asymptomatic. Recog-
nition may be difficult since the standard preaccess duplex
ultrasound workup may not visualize this area well.
Clinical and noninvasive “hints” may suggest central
vein stenosis or obstruction before AV access construction.
Although the history should inquire about prior catheter-
ization, not all patients will recall this treatment. Typical
scars accompany the insertion sites for tunneled catheters,
pacemaker leads, defibrillator leads, parenteral nutrition,
triple lumen, and PICCs. All of these central venous devices
have a high incidence of thromboses in the axillary, subcla-
vian, innominate, jugular veins, and vena cavae that will
compromise the options for subsequent AV access.74-79 A
PICC directly damages the cephalic and basilic veins, but
may also impede recognition of central obstruction because
of its peripheral insertion site.78,79 Central vein catheteriza-
tion is now the most common primary cause of central vein
thrombosis.80 The actual incidence of central vein throm-
bosis may be under-appreciated, however, because ultra-
sound transmission is limited by the clavicle and sternum in
these anatomic distributions.81
Once the access has been constructed, obstruction may
produce clinical findings of regional edema and high ve-
nous pressures. In addition to the inconvenience of persis-
tent edema, AV access use may be compromised by diffi-
culty with needle access and the potential for recirculation.
Axillary, subclavian, and innominate vein obstruction are
associated with unilateral findings; vena caval obstruction
produces bilateral findings. If the superior vena cava (SVC)
is occluded, this generally means the loss of both upper
extremities for subsequent AV access placement.
A strong pulse (vs a palpable thrill) in the AV access
conduit may suggest outflow obstruction. Inspection of the
extremity and the central outflow anatomy may identify an
extensive collateral pattern located across the anterior
chest, shoulder, and along the flank. SVC obstruction or
stenosis can produce a large swollen head, neck, and shoul-
der, with large chest wall collateral veins, and a feeling of
head and neck fullness and dyspnea. Airway compromise,
dizziness, mental changes, and visual problems including
blindness may supervene.82-85
The severe V-HTN produced with a functioning AV
access may also produce the typical extremity findings
associated with chronic venous insufficiency, including pig-
mentation, thickening, induration, and even ulceration of
the skin.72,73,86-91 Patent side branches between the anas-
tomosis and an outflow stenosis in an autogenous AV
access,92,93 or a radiocephalic side-to-side anastomo-
sis,89,90 divert the AV access flow into the patent collateral
venous bed, resulting in distal edema. Persistence of V-
HTN will typically produce these symptoms in the first
through fourth digits of the hand. The distribution local-
izes to the pressurized venous bed. This may be mistaken
for infection, but will only resolve with correction of the
V-HTN.88,90,93
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Flow in the radial artery increases from 30 to 300
mL/min after construction of a radiocephalic AV access.94
Mean flow using ultrasound-detected indicator dilution is
645 mL/min for radiocephalic and 1336 mL/min for
brachiocephalic autogenous AV accesses.95 Even well-de-
veloped collaterals may have difficulty managing this 10-
fold increase in arterial volume flow.
The most frequent cause of upper extremity venous
thrombosis is now central venous catheters or cardiac de-
vices; the most powerful predictor is the presence of these
devices, with an odds ratio of 7.3 (95% CI, 5.8-9.2).80,81
Approximately 50% of dialysis patients had a history of
subclavian catheterization, and 50% of those exposed had
stenoses that were considered significant.96 A Belgian study
detected significant subclavian vein stenosis or obstruction
by venography in 19% of patients who had received dialysis
through a subclavian catheter.74 A 10-year review of pace-
maker insertions at one institution found a 71% incidence
of significant subclavian vein obstruction; ligation of an
ipsilateral AV access was required in 10 of 14 dialysis
patients.75 A review of defibrillator lead placements found
14 of 30 had 50% subclavian stenosis.76
Althoughmost thrombi were peripheral in venographic
reviews of PICCs, the overall incidence of 38% has direct
implications for all dialysis patients.78,79 Thrombus was
occlusive in 86%, 38% were basilic or cephalic vein, and 12%
central vein thrombi.78 A 29% incidence of unsuspected
central venous stenosis was prospectively observed in pa-
tients with functioning prosthetic AV access who had
venography for evaluation of a known anastomotic outflow
stenosis.97 These stenoses are often short, web-like, and
focal.95
There is minimal literature comparing the cutaneous
effects of V-HTN with that of lower extremity chronic
venous insufficiency.91 Pericapillary cuffs, dermal edema,
and intimal proliferation were observed in biopsy speci-
mens taken from the index finger or first web space of
patients with upper extremity access grafts and signs of
venous hypertension.89,90 Peroxidase-antiperoxidase stain-
ing confirmed the presence of fibrin.90 Monoclonal anti-
bodies and immunofluorescence studies confirmed the
presence of fibrin in the cuffs as well as plasminogen acti-
vator inhibitor-1; the latter is suggestive of impaired break-
down of fibrin. Less extensive fibrin cuffs were also ob-
served in two side-to-side autogenous AV accesses, but
none in three end-to-end autogenous AV accesses or con-
trols.89
Central venous stenosis or occlusion
Because clinical and duplex ultrasound assessments
may not accurately reflect subclinical central vein obstruc-
tion, identification and correction may require complete
visualization of the anatomy of the proposed AV access site
and its outflow veins. Venography is essential to determine
whether the vein is occluded or stenotic; even if it is
occluded, passage of a guidewire opens up therapeuticoptions. Recognition of central vein stenosis before access
placement is generally a contraindication to use of that
extremity, unless the venous stenosis can be corrected. If it
develops after construction of the AV access, the focus is on
resolution of the symptoms of V-HTN as well as preserva-
tion of the AV access site.
Endovascular: angioplasty and stenting. Endovas-
cular approaches to treat venous outflow stenosis offer
minimal risk and a reasonable initial technical success rate;
however, durability has only been mediocre, and continued
function may require repeat intervention. The SVC is ame-
nable to thrombolysis, angioplasty, and stenting.82-84,98,99
Stenting SVC obstruction produced a more durable pa-
tency than open repair for benign etiologies, such as cath-
eters, and pacemakers, in the most recent report from the
MayoClinic.99 A 12-month patency of 67%with an assisted
patency of 100% was achieved by stenting to a diameter of
8 to 12 mm in the SVC.83 The purpose of the stent is to
prevent elastic recoil associated with the need for repeat
percutaneous transluminal angioplasty (PTA).
The same interventions are available for treatment of
the innominate vein.83,84,98,100 Results of these procedures
in the subclavian and internal jugular veins are satisfactory,
but subclavian stents may be complicated by the scissoring
effects of the first rib and the clavicle, resulting in perma-
nent deformation. A summary of these interventions over
the past decade reported a 12-month patency ranging from
11% to 68% for central venous stents and 11% to 35% for
PTA alone.83
Open surgical management: bypass and interposi-
tion grafts. Surgical management options include a direct
approach to the site of obstruction, bypass of the obstruc-
tion, construction of the access in another extremity, and
conversion to peritoneal dialysis. The direct approach in-
cludes a number of creative surgical options: jugular turn-
down, axillary–jugular bypass, axillary to contralateral ve-
nous outflow, and even atrial bypass.101-104 The best
results with SVC and innominate vein procedures have
been with autogenous vein–spiral saphenous and femoral
veins.82,84,105 With moderately reduced long-term pa-
tency, PTFE is acceptable in this anatomic site. At 4 years,
secondary patency for spiral saphenous vein graft was 90%
and 50% for PTFE. Both reflect secondary patency achieved
by initial surgery with additional endovascular interven-
tions.82,99
Although not optimal, the physician can justify contin-
ued use of the extremity with moderate venous obstruction
in some situations. These include a paucity of reasonable
options for new AV access and relatively mild symptoms
from the V-HTN. In patients who have few AV access
alternatives, the burden of a chronically swollen extremity
may become relatively acceptable.
Clearly, avoidance of the central venous catheterization
in the first place is the most effective method of eliminating
this problem. Patients with impending chronic renal failure
constitute a relatively small population of those requiring
pacemakers or defibrillators. When these choices are elec-
tive, consideration of the subsequent need for access should
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dominant upper extremity, which is usually the left.75-77,79
This has been emphasized by the Fistula First initiative and
is strongly supported by data demonstrating a significant
increase in the morbidity associated with patients com-
mencing dialysis with a catheter.3,106
Results of treatment. The literature on this compli-
cation is based on small case series and thus is limited. The
best results have been obtained when the AV access is
constructed and matured before hemodialysis commences.
When this program is successful, catheter complications can
be largely eliminated.
Endovascular options offer a minimally invasive ap-
proach with relatively low risk and immediate restoration of
functional AV access. Although durability is only mediocre,
these factors favor this as an initial approach, with the caveat
that repeated intervention is frequently necessary to main-
tain the result. Surgical approaches are more invasive, but
provide greater durability. However, the prolonged paten-
cies that were described were only achieved with adjunctive
secondary endovascular interventions. The durability of
these solutions depends on the reconstruction used: Au-
togenous reconstructions have the best track record, with
PTFE as an acceptable second choice.82,84
Valvular insufficiency
When the autogenous AV access was initially intro-
duced, considerable debate ensued about the best method
of construction. Technically, a side-to-side anastomosis was
more straightforward, had higher flows, and was less prone
to early thrombosis.87 It was assumed that the valves in the
distal venous limb would remain functional, preventing
retrograde flow into the distal, superficial veins. This did
not always occur, however, and some limbs with side-to-
side anastomosis developed high-volume retrograde flow
resulting in the typical findings of chronic venous insuffi-
ciency (edema, pigmentation, induration, and ulceration).
Unless the practitioner is familiar with the findings of distal
V-HTN, the symptoms may be mistaken for infection or
allowed to persist until infection supervenes.88,90,93
With a side-to-side radiocephalic AV access, these find-
ings were most commonly seen on the thumb and index
finger, presumably because the incompetent valves produc-
ing the V-HTN were in the distal drainage pattern of the
cephalic vein.72,87 The appropriate management is to con-
vert the side-to-side configuration to a functional end-to-
side by ligation of the incompetent, distal outflow
vein.72,87
For a new autogenous AV access, end-to-side construc-
tion is now standard procedure. However, V-HTN may
still occur when the outflow from an end-to-side radioce-
phalic fistula is obstructed proximally and the branch veins
conduct the same retrograde pressure pattern. In this set-
ting, the distribution is more likely to occur in the index,
middle, and ring fingers because the retrograde flow is
transmitted through the remaining superficial veins.88,92,93
Management options include ligation of the incompetent
branch vein feeding the distal superficial veins or relief ofthe obstruction, or both.73,87,92 Alternatively, if the access
site can be sacrificed, the AV access can always be ligat-
ed.72,88,92,93 A similar syndrome may develop with an
prosthetic AV access when intervening branches are present
between the outflow anastomosis and a more proximal
obstruction in the outflow vein.
Results of treatment. Resolution of venous outflow
obstruction can often be achieved. Construction of a side-
to-side AV access should generally be avoided. Clinical
recognition is the key to successful treatment. When accu-
rately characterized anatomically, ligation of the incompe-
tent branch vein results in resolution of symptoms.
Regional outflow obstruction
Prosthetic AV accesses are commonly found to have
intimal hyperplasia at the outflow anastomosis. Rather than
producing edema and V-HTN, outflow anastomotic steno-
sis results in high venous pressures, poor dialysis from
recirculation, and ultimately, thrombosis. However, when
outflow obstruction occurs in a more proximal vein, a
functioning autogenous or prosthetic AV access may also
produce V-HTN with complicated drainage patterns that
are difficult to visualize and correct. Rising venous pressure
is considered a sensitive indicator of outflow obstruction.
Venography may be required to identify these flow patterns
and to accurately localize the site and extent of the obstruc-
tion.
The KDOQI guidelines hypothesize that a stenosis of
50% in an autogenous or prosthetic AV access outflow
predisposes to early thrombosis with permanent loss of the
AV access.2 Accordingly, serial surveillance is recommen-
ded for the purpose of identifying these stenoses, with the
expectation that treatment of the stenosis will prevent
thrombosis and improve the functional life of an autoge-
nous or prosthetic AV access. Surveillance includes mea-
surement of recirculation, dialyzer flows during treatment,
duplex Doppler imaging, and derived AV access flow.2 The
more accurate ultrasound-detected indicator dilution
method has recently been introduced to observe serial AV
access flows.95,107-110
Supporting the concept of surveillance, Schwab et al111
measured elevated venous pressure in 73 patients for fur-
ther evaluation: 15 declined, eight had no stenosis, and
venography showed 50 had 50% lumen diameter reduc-
tion. Initial treatment with PTA was followed with repeat
PTA or surgical revision. Stenoses were located at the
outflow anastomosis, the outflow vein, and the subclavian
vein in this group of predominantly prosthetic AV accesses.
In comparison with a historical control group and the
concurrent nontreatment (refused intervention) group,
the authors concluded that elective intervention reduced
the rate of thrombosis or loss of access.111
Results of treatment. Four completed randomized
trials with similar conclusions assessed the concept of elec-
tive, preemptive intervention for venographically con-
firmed 50% venous stenosis.112-115 After angiographic
confirmation of50% stenosis, 64 patients with prosthetic
AV accesses were randomized to PTA or observation. Re-
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intervention group if 50% stenosis recurred. The two
groups did not differ significantly in terms of thrombosis or
functional access failure.112
In another trial, 58 patients with prosthetic AV accesses
and venous anastomotic stenosis of 50% were random-
ized to PTA or PTAwith an adjunctive stent. No significant
difference was noted in access thrombosis, need for surgical
revision, or need for a repeat PTA.113 In yet another trial,
34 patients with stenoses of 50% at or 3 cm of the
outflow vein–prosthetic graft junction or in the peripheral
outflow vein were randomized to PTA or PTA with an
adjunctive stent. The authors concluded that stent place-
ment offered no advantage.114 The fourth trial randomized
43 patients with venous anastomotic stenosis of 50% to
PTA or surgical revision (patch angioplasty or an interpo-
sition graft). Surgical median patency of 12months differed
significantly (P  .01) from the PTA median patency of 4
months.115 The results of these randomized trials are diffi-
cult to interpret but suggest that prophylactic intervention
may not be helpful, that stenting offers no advantage, and
that surgical revision is better than PTA.
Stenosis at the arch of the cephalic vein outflow into the
axillary vein is problematic. The vein is fragile, has a greater
incidence of rupture, is most frequently involved with
brachiocephalic AVFs, and is anatomically inhospitable to
stent therapy.116,117 In this setting, a direct surgical trans-
position procedure to reroute the cephalic vein outflow to
the more distal axillary or brachial vein performed
well.117,118 Outflow transposition is also effective for ba-
silic vein stenosis.118
Two randomized trials with similar conclusions address
the role of surveillance monitoring of AV access flow.109,110
Both used ultrasound-detected indicator dilution in an
experimental group compared with observation or clinical
monitoring alone. Both randomized 100 subjects, and
surveillance was conducted monthly or every fourth
month. Both found that the frequency of intervention with
angioplasty was significantly higher in the experimental
group, but that it had no effect on the end points. Neither
protocol resulted in an improved interval to thrombosis or
to permanent prosthetic access failure. Both concluded that
surveillance increased interventions but without demon-
strable efficacy.109,110 These findings are consistent with
those focused on anatomic stenoses as described previously.
The utility of surveillance monitoring is discussed in detail
in the Clinical Practice Guideline.119
Recommendations
The available data demonstrated no clear advantage of
angioplasty with or without stenting compared with obser-
vation; thus, there is nomandate for elective intervention to
correct 50% stenosis in the absence of other abnormali-
ties. However, because functional use of the access may be
compromised by stenosis, PTA may still have a role as a
bridge to more definitive therapy. Surgical intervention
with patch angioplasty, interposition grafting, or transpo-
sition will resolve the symptoms of V-HTN and preserve afunctional access. A systematic review is in progress at the
Cochrane Collaboration.120 Numerous authors contribut-
ing written opinions on the topic have advocated a random-
ized prospective trial to evaluate preemptive therapy for
stenosis or flow reduction identified during the recom-
mended surveillance.121
ARTERIAL STEAL SYNDROME
● Arterial steal syndrome is predominantly a clinical di-
agnosis
X Evidence of flow diversion is common but most
patients are asymptomatic
X Unilateral complaints should prompt consideration
of a diagnosis of steal
X Incidence is 0.25% to 1.8% in autogenous AV access
and 4% to 9% in prosthetic AV access
X Pain, motor, and sensory complaints involve multi-
ple nerve trunks
X Isolated digital necrosis: consider steal or distal ar-
teriosclerosis, or both
X Isolated neurologic symptoms also suggest ischemic
monomelic neuropathy (IMN) or entrapment
X Inflow arterial obstructive disease is uncommon in
the upper extremity, but should be suspected when
clinical steal combines with low AV access flow.
● Common risk factors for high-flow arterial steal in-
clude
X Brachial arterial origin
X Diabetes mellitus
X Female gender.
● Management options
X Ligation: Solves the problem, but requires sacrifice
of the access; appropriate for severe symptoms and
IMN
X Banding: More likely to succeed in high flow AV
access, but often complicated by thrombosis
X Rerouting of arterial inflow: Extension of the arterial
anastomosis with or without brachial ligation (distal
revascularization and interval ligation [DRIL], revi-
sion using distal inflow [RUDI], and proximaliza-
tion of the arterial inflow [PAI]) will retain a well-
functioning AV access and resolve symptoms in
most patients.
Within 5 years of the introduction of the Brescia-
Cimino-Appel AV access, disabling neurologic symptoms
in the forearm and hand were attributed to arterial steal
syndrome from radial and brachial AV accesss.71,122,123
The clinical findings of ischemic neuropathy (ie, severe
pain, motor and sensory impairment, and involvement of
multiple nerve trunks) were accurately described by
Bolton,124 a clinical neurologist with an interest in neuro-
logic dysfunction in patients with uremia.
Clinical features of symptomatic and asymptomatic
arterial steal syndrome
The clinical spectrum of arterial steal is wide because
most patients are not symptomatic but have laboratory
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fested by pulse deficits, Doppler signal attenuation, and
distal flow reversal, may be present with AV access but only
becomes symptomatic when blood flow is shunted (stolen)
from tissue beds distal to the arterial anastomosis.
Mild ischemia produces slight coldness and numbness
that occurs only during dialysis, may be self-limited, and
may resolve without treatment.
Severe ischemic symptoms of arterial steal syndrome can
be permanent and may be associated with constant pain,
severe numbness, digital cyanosis or gangrene, finger con-
tracture, or amputation of a digit, hand or forearm. Symp-
tomatic arterial steal syndrome is uncommon, but usually
requires surgical intervention. Although symptomatic steal
can occur with a forearm AV access, the incidence is low,
ranging from 0.25% to 1.8%.53,72,125,126 Severe symptom-
atic arterial steal syndrome is most frequently associated
with a brachial arterial source, with a frequency of 4% to
9%.53,72,123,125,127-132 Diabetes mellitus50,125,127,129-131
and female gender72,128,130,132 are present in more than
half of the reported cases. Other associated risk factors
include previous ipsilateral AV access, peripheral athero-
sclerosis, and age.130 Gender and diabetes cannot be al-
tered, but the need for anastomosis to the brachial artery
can be reduced by preferential use of proximal radial artery
inflow for the initial procedure or as treatment for
steal.133,134
Between 50% and 66% of patients who develop steal do
so 1 month of surgery.135 Steal syndrome may occur
immediately or evolve over several weeks and is often
exacerbated during dialysis.127,128,131,136,137 The diagno-
sis is predominantly clinical and confirmed by unilateral
neurologic complaints associated with digital tissue necro-
sis, pallor/cyanosis of the distal extremity, reduced arterial
flow distal to the anastomotic site, and reversal of flow in
the distal artery.
Complicating an accurate diagnosis in these patients is
the recognition that digital gangrene is probably due as
much to advanced atherosclerosis in the hand and forearm
as to arterial flow diversion.138 Yeager et al138 found an
equal distribution of digital gangrene in extremities con-
tralateral to the access and confirmed the severity of radial,
ulnar, and digital arterial occlusions. Thus, arteriography is
useful to define the problem and may identify an unex-
pected proximal stenosis.
The diagnosis of steal is less likely when AV access flow
is lower than expected or necrosis is present without other
characteristics of steal. When ulceration and localized
edema are present, steal must be differentiated from re-
gional venous hypertension. When the complaints are only
neurologic, consideration should be given to IMN and
entrapment.
A critical but infrequent and easily overlooked problem
associated with steal syndrome is proximal arterial steno-
sis.139-141 Just as exercise brings on symptoms of claudica-
tion with subcritical stenoses, increased flow demand asso-
ciated with an AV access may unmask arterial stenoses that
were not significant at resting flows. Although upper ex-tremity occlusive disease is generally uncommon, it should
be suspected more frequently in patients with ESRD.
Contrast arteriography may be beneficial in planning
treatment and an endovascular approach may simplify
correction.139-141 A preoperative evaluation of adequate
proximal inflow is a familiar consideration when a lower
extremity access is constructed.140
An important differential diagnosis to consider in a
patient with severe symptoms despite normal physical find-
ings and a palpable pulse distal to the access is IMN.142,143
This diagnosis can be very difficult to make, because this
form of steal affects only the median, radial, and ulnar
nerves but not the skin or muscles.
A thorough physical examination before an AV access is
performed includes a blood pressure examination of both
upper extremities and an Allen test to confirm the presence
of an intact palmar arch. Routine testing beyond a physical
examination is not necessary unless the results are abno-
rmal.144
Pathophysiology and diagnostic testing
Clinical evidence of flow diversion is observed in90%
of upper extremity AV access when evaluated by Doppler
augmentation or pressure studies. Approximately one-third
of a prospective study cohort had no radial pulse after
brachial AV access was constructed.128 About 73% of ra-
diocephalic AV access and 91% of brachial-axillary, pros-
thetic AV access (8 mm) demonstrated reversed flow in the
distal artery grafts.145
Supporting the clinical observation that brachial inflow
is associated with flow-related steal are studies with ultra-
sound dilution and electromagnetic flowmetry in newly
constructed AV access.95,145 Both methods consistently
reported that brachial-based AV access had twice the flow
of radial-based AV access.95,145 Arterial steal has beenmore
pronounced with lower extremity AV access and was once
considered a major negative factor to their use.146
Attempts to predict symptomatic arterial steal syn-
drome preoperatively are confounded by the high inci-
dence of flow diversion after an AV access is constructed.
Various investigators have used digital plethysmography in
an attempt to characterize a critical threshold for ischemia.
Although not always predictive, these thresholds offer
some guidance for flow-adjustment therapies. The pro-
posed criteria are pressures of 50 to 60 mmHg or an index
of 0.4 to 0.6 measured with a digital or forearm cuff after
AV access construction.126,128,132,147
In patients with unrecognized or uncorrected steal,
persistence of severe ischemia may produce devastating
results, such as a nonfunctional extremity with unremit-
ting chronic pain or gangrene with loss of digits or
limbs.53,72,127,130,135,148
Management, treatment, and results
When severe hemodynamic steal syndrome occurs or
IMN is diagnosed, immediate ligation or physiologic
restoration of flow is appropriate. If intervention is de-
layed 1 week, reported results are poor and interven-
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ment.3,124,127,131,136,137,142 In a small series of four
patients, the AV access was deconstructed in each patient
but only after 8 weeks. The pain syndrome improved after
12 months, but motor function did not improve.136 Red-
fern and Zimmerman127 reported partial or complete re-
covery of motor and sensory findings in seven of eight
subjects when intervention occurred between 1 day to 6
months after AV access construction.127 Although the
symptoms appeared to be less severe, two of six subjects
who were treated2 weeks of access construction achieved
better resolution of symptoms.131 Claw hand with severe
persisting pain may result when corrective surgery is unsuc-
cessful.3,137
Ligation or deconstruction of the access. The sim-
plest and most reliable method for treating dialysis access–
induced ischemia is ligation of the conduit. However, in
addition to sacrificing the access site, this strategy requires
placement of a new AV access and is of particular concern
for those with limited availability of access sites. Occasion-
ally, angioplasty of a proximal arterial stenosis or coil em-
bolization of distal reversed inflow may effectively address
symptoms of steal.139,140,149
Restriction of flow: banding or tapered conduit. Band-
ing of an AV access can provide improved native arterial
flow by deliberately narrowing the venous outflow to in-
crease resistance through the access and thus increasing
perfusion to ischemic distal tissue beds. Reducing the flow
into the access is the goal of banding. Although this is more
likely to succeed with a high-flow access, it may lead to
thrombosis in those with a low-flow access. Some centers
have successfully used controlled reduction of autogenous
AV access flow by banding, but objective criteria measuring
the amount of banding necessary to eliminate distal isch-
emia while maintaining a functional access is lack-
ing.126,150,151 As a result, thrombosis of the access is com-
mon after banding. Although flow restriction has offered
little advantage in upper extremity access, a controlled
intraoperative anastomotic taper may revitalize consider-
ation of lower extremity access procedures for individuals
whose upper extremity sites are exhausted. In consecutive
case series, this technical innovation successfully controlled
steal with transposition of the larger diameter femoral
vein.146,152
Rerouting of arterial inflow: DRIL, RUDI, and
PAI. Schanzer et al153 in 1988 described a novel tech-
nique termed distal revascularization and interval ligation
(DRIL), which offers preservation of the access with phys-
iologic restoration of flow to the hand. A DRIL procedure
involves two parts: a bypass and interval ligation of the
native artery. The bypass graft is connected to the artery
proximal to the access anastomosis and its outflow directed
to the native artery distal to the access anastomosis. The
reversal of blood flow is eliminated by ligation of the artery
distal to the AV access, providing the distal vascular bed
with normal perfusion pressure and flow.
Schanzer et al154 reported their updated experience
with DRIL procedure in 2004. Complete relief of symp-toms was achieved in 34 of 42 patients. Only partial im-
provement was seen in the remaining eight patients due to
irreversible ischemic neuropathic changes at the time of the
procedure. The cumulative patency rate at 1 year was 96%
for bypasses, 100% for autogenous AV access, and 73% for
prosthetic AV access.
Lazarides et al128 reviewed 180 AV accesses originating
from the brachial artery in an effort to better characterize
the relationship between steal and permanent neurologic
dysfunction. Those with severe sensorimotor symptoms, as
described earlier, were treated 24 hours with a DRIL
procedure, with complete resolution of ischemic symp-
toms. An attempt was made to select those with greater
severity of ischemia on the basis of a wrist/brachial index
combined with selective performance of nerve conduction
studies. Repetitive nerve conduction studies improved in
most of the treated limbs.
The DRIL procedure is generally effective but is signif-
icantly more involved and morbid than banding. Although
symptomatic steal from a distal radiocephalic AV access is
uncommon, bypass and ligation is a less attractive option
with these smaller arteries. Simple interruption of the distal
radial artery to arrest the reverse flow is straightforward and
may be approached surgically or with endoluminal coil
embolization.149 A major consideration with the DRIL
procedure is loss of the native artery.
Other novel solutions have focused on the basic con-
cept of rerouting the arterial inflow. Recognizing that
brachial arterial origin was a common feature of symptom-
atic steal, others have reported success with extending the
arterial end of the access distally to smaller arteries with
revision using distal inflow (RUDI) and proximally to
larger arteries with proximalization of arterial inflow
(PAI).134,155 Each of these management solutions is based
on small case series involving an uncommon but clinically
significant complication of AV access. More experience is
needed before an appropriate solution can be recomme-
nded.
Recommendations
When severe neurologic findings occur, physiologic
ischemia should be addressed immediately because neuro-
logic injury may not be reversible once it has occurred. The
only treatment associated with neurologic improvement
was correction of the ischemia at the earliest opportunity
after recognition. Prevention is an even better approach;
although it is impossible to avoid diabetic patients or
women with ESRD, brachial arterial anastomoses should
be avoided whenever possible. Although this is again
subject to anecdotal evidence, alternative placement of
the arterial anastomosis on the proximal radial artery is
thought to reduce development of arterial steal synd-
rome and IMN.133,156
HIGH-OUTPUT CARDIAC FAILURE
● A rare complication characterized by symptoms indis-
tinguishable from cardiac failure. Because cardiac fail-
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tion, differentiation is difficult. The sine qua none is
improvement after treatment.
● Essentially a complication of autogenous AV access.
● Attempts to correlate AV access flow with cardiac
output have suggested an AV access flow3 L/min or
an AV access flow that is30% of the cardiac output is
consistent with the diagnosis.
● A decrease in cardiac output after transient occlusion
of the AV access is suggestive of the diagnosis.
● Management options
X Ligation—solves the problem if due to AV access
overload, but requires sacrifice of the access
X Flow restriction Banding—is a more attractive op-
tion in the setting of large AV access and AV access
flows.
Autogenous AV access for maintenance hemodialysis
was usually well tolerated, but high-output cardiac failure
was reported within a decade of its introduction.157 Symp-
toms of heart failure have multiple etiologies and are very
common in the ESRD population. This rare complication
accounts for a minimal proportion of these.
High-output cardiac failure is primarily associated with
autogenous AV access because no known report implicates
a prosthetic conduit. Excessive AV access flow should raise
reasonable suspicion, but this rare morbidity may still occur
with normal AV access flows. As a result, delay in diagnosis
is common.
Although high output cardiac failure remains uncom-
mon, the current sparse literature attempts to address rec-
ognition using new and better physiologic measurement
techniques. To date, the only convincing evidence that
these symptoms are not from intrinsic cardiac disease or
other correctable conditions is resolution of the complaints
by ligation or banding of an AV access. Resolution of
symptoms remains the sine qua none of diagnosis.94,157-162
Clinical features of access-related high-output
cardiac failure
High-output cardiac failure is defined as “symptoms of
cardiac failure in the presence of an above-normal cardiac
index (2.3 L/min/m2).”158 The typical symptoms and
findings are those of right heart failure: dyspnea at rest,
dyspnea on exertion, orthopnea, paroxysmal nocturnal dys-
pnea, reduced exercise tolerance, peripheral edema, pulmo-
nary edema, cardiomegaly, increased blood volume, tachy-
cardia, and a hyperdynamic cardiac output.158 Although
not very accurate for the diagnosis of high-output cardiac
failure, temporary occlusion of the high-flow AVF may pro-
duce a reduction in pulse rate—theNicoladoni-Branham sign.
The decrease in pulse rate is a baroreceptor reflex mediated
by the vagus.160,163 One report estimated that the mean
slowing of the pulse rate in recognized high-output cardiac
failure was approximately 7 beats/min.163
Because 31% to 36% of dialysis patients have cardiac
failure at the initiation of dialysis therapy, the clinical dis-
tinction between high-output cardiac failure and intrinsiccardiac disease remains difficult.27,28 Further complicating
recognition is that heart failure subsequently develops in an
additional 25% during their dialysis lifetime.28 An abnor-
mally elevated cardiac output that decreases with temporary
occlusion of the AV access would help differentiate this
condition from intrinsic cardiac insufficiency.
The more difficult diagnostic dilemma arises, however,
when the cardiac output is relatively low.The poorly function-
ing heart may be unable to increase output when a large
proportion of output is obligated toAV access flow. Thus, it is
difficult to validate a specific diagnostic criterion for high AV
access flow or an abnormal cardiac index due to the inherent
variation between individuals. At one extreme, a young,
trained athlete was able to compensate until autogenous AV
access flow reached 19.4 L/min when symptoms of failure
developed.163 In contrast, others have reported high-output
cardiac failure with AV access flows as low as 0.8 to 1.0
L/min.94,157 According to the existing literature, the prog-
nosis for high-output heart failure is excellent, as long as the
cause is recognized and treated.94,157-160,163These guidelines
attempt to definewhichESRDpatient is at risk of high-output
cardiac failure.
Because high-output cardiac failure is rarely encoun-
tered in most dialysis units, diagnosis is likely to remain
elusive. Although literature citations for this are exception-
ally uncommon, if the problem is an obligate increase in
cardiac output, it would be logical to expect that the
pulmonary circulation would also be compromised in sus-
ceptible individuals. Indeed, several recent reports have
now appeared demonstrating pulmonary hypertension that
has responded to adjustments in the autogenous ac-
cess.161,162
Improved methods for noninvasive characterization of
AV access flow and cardiac output will distinguish AV
access–related high-output cardiac failure from other com-
mon causes of these symptoms, such as anemia, hyperten-
sion, inadequate dialysis, and fluid/electrolyte reten-
tion.157,160 Recent advances in medical management of
these problems have addressed these issues with erythro-
poietin, better antihypertensive therapy, and improved di-
alysis techniques.
Pathophysiology: role of AV access flow and cardiac
output measurements
Development of validated methods for the minimally
invasive determination of accurate AV access flow rates
should help to define this major risk factor for high-output
cardiac failure. The indicator-dilution technique with ultra-
sound detection was introduced in 1996 andmeasures flow
in the access during the time of dialysis. The mean absolute
error between duplicate access flow measurements was
5.0%  3.8%; the mean absolute error compared with
duplex Doppler (off of the dialysis machine) was 9.2% 
7.2% in seven subjects.107 The technique has subsequently
been validated by correlation against two other techniques:
magnetic resonance arteriography (r  0.91, P  .001),
and intra-access flow pressure curves (r  0.84, P 
.001).108 Serial ultrasound dilution measurements are now
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flows and have been used in randomized and prospective
trials.2,109,110
Early reports describing this rare and unusual compli-
cation were summarized in a 1976 review that measured
access flow with an electromagnetic flowmeter.157 By 1995
“invasive measurements” were used to describe improve-
ment in cardiac function before and after ligation159 and
duplex-derived AV access flows were described in 1998.163
Subsequently, the ultrasound dilution method for mea-
surement of AV access flow, a more accurate examination,
has been used to attempt to define what constitutes “too
much flow.”94,158,164 But AV access flows as low as 0.8 to
1.0 L/min measured with the earlier techniques were be-
lieved to have produced high-output cardiac failure by the
standard of clinical resolution of symptoms of failure.94,157
Thus, the relationship between AV access flow and cardiac
output probably involves more parameters than flow alone.
Physiologic changes accompanying an AV access be-
come more pronounced as the volume of AV access flow
increases, including increased heart rate, increased cardiac
output, and increased blood volume. A strong relationship
between access flow and cardiac output (r 0.62, P .01)
was defined by the equation: AV access flow  0.20 
cardiac output  0.06.164
Previous attempts to correlate clinical cardiac failure
with AV access flow rates faltered because of the wide
variation between individuals. On the basis of these find-
ings, the ratio between autogenous AV access flow and
cardiac output of 30% to 35% has been suggested as a
screening threshold for serial surveillance for high output
cardiac failure.158,164
A summary of the findings from numerous reports
indicates that “normal” autogenous AV access flows range
from 1126 to 1922 mL/min; however,15% to 23% were
still2.0 to 2.5 L/min.158Using serial ultrasound dilution
in a prospective study of access flows between 6 and 28
weeks after construction, a study documented higher flows
(mean, about 1300mL/min) in both male sex and brachial
vs radial, AV access. A trend toward lower flows was noted
in diabetic patients.95 Because a brachial AV access has
almost twice the flow of a radial, one would expect these
higher AV access flows to predispose to high-output cardiac
failure.158 MacRae et al158 suggested that the diagnosis be
entertained when the AV access flow rate 3 L/min or
30% of the ratio of AV access flow to cardiac output.
Management and treatment options
Reduction of flow through the conduit or ligation of
the AV access is appropriate management once the diagno-
sis is convincingly established. Although flow reduction
procedures have had little success in relation to the more
common problem of arterial steal, revision of an enlarged
anastomosis or banding of a dilated autogenous access has
been a more useful alternative for treatment of high-output
cardiac failure. A German group commented that they had
successfully managed this complication with banding and,
therefore, never needed to ligate an AV access for high-output cardiac failure.94 Successful resolution of the
symptoms of failure by banding or anastomotic revision
has been reported by several authors, with continued
functional utility of the hemoaccess site.94,107,157 De-
construction of the AV access by ligation also resolves
the symptoms of cardiac failure at the price of loss of the
site; ligation may be the most appropriate treatment
when no further need exists for the access—such as
successful transplantation.157,159-163 In one report, renal
allograft function also improved.159
Literature on this rare and unusual complication re-
mains sparse and characterized by clinical case analysis.
High-output cardiac failure is uncommon, but enough
detailed reports have described resolution of the clinical
findings with physiologic adjustment of AV access flow to
justify consideration of the diagnosis in appropriate clinical
situations. Because of the prevalence of cardiac failure in the
dialysis population, consideration of high-output failure
must be individualized. Currently, no specific threshold of
AV access flow or cardiac output defines high-output car-
diac failure. Although 2.5 L/min is the upper limit of flow
in most AV access, this value exceeds that required to
produce remediable symptoms in some reported cases.
Further evaluation of the flow/cardiac output ratio may be
beneficial. Response to treatment remains the sine qua none
of this diagnosis.
NEUROPATHY
● Peripheral neurologic dysfunction is a common (70%)
morbidity of advanced renal insufficiency. It may be
difficult for even well-trained experts to distinguish
between these neuropathies.
● Ischemic neuropathy: unilateral involvement of all
three forearm nerve trunks
X May have immediate or delayed onset
X Pain, paresthesias, numbness out of proportion to
physical findings
X Weakness and paralysis: radial, ulnar, and median
distribution
X Electrodiagnostic studies may assist in differential
diagnosis
X Deconstruction or revision of AV access provides
the best outcome.
● Entrapment: this focal mononeuropathy may be ame-
nable to decompression
X Carpal tunnel release–Median nerve
X Ulnar nerve:
– Cubital tunnel release
– Ulnar canal release.
● Uremic and diabetic polyneuropathy are both
X Characterized by bilateral symmetry
X Worsen with the duration of the primary condition.
Neuropathic findings are generally more common than
not in patients with ESRD. This section will focus on those
neurologic symptoms relating to the management of the
AV access. Most patients with ESRD have chronic, sym-
metrical polyneuropathy that responds to little besides
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alert for two other etiologies that may respond to interven-
tion. Ischemic neuropathy related to AV access involves
multiple nerves in a single extremity (monomelic) and is
most likely to improve when corrected immediately. En-
trapment neuropathy is a mononeuropathy amenable to
focal surgical intervention.
Accurate diagnosis of postoperative sensorimotor com-
plaints requires a satisfactory preoperative neurologic ex-
amination in addition to the obvious arterial and venous
assessment. Although it would seem that these etiologies
are relatively distinct, in practice, even experienced clini-
cians have found it difficult to differentiate between these
neuropathic syndromes. Electrodiagnostic studies have a
wide range of normal values, but may localize specific site
dysfunction or confirm a difference between extremities
when systemic neuropathy is present. By facilitating differ-
ential diagnosis, electrodiagnostic examination may reduce
the delayed recognition associated with adverse outcome.
Ischemic monomelic neuropathy
(ischemic neuropathy?)
The rare but devastating complication of IMN is dis-
tinguished by dysfunction of multiple peripheral nerve
trunks in a single extremity in the apparent absence of
arterial insufficiency. Initial descriptions of IMN reported
neurologic abnormalities in clinical situations where acute
arterial ischemia was prolonged, but subsequently cor-
rected. In practice, symptoms may begin within hours.
Clinical features of IMN. The term IMN was intro-
duced by Wilbourn in 1983, a neurologist at the Cleve-
land Clinic, and was intended to distinguish isolated
ischemia of the arterial supply to multiple nerves of a single
extremity.142 The term refers to the combination of isch-
emia and neuropathy in a single limb (melos is Greek for
limb). Descriptive and treatment recommendations are
both derived from observational data.
Neurologic symptoms may become manifest immedi-
ately after construction of hemoaccess and should be spe-
cifically assessed.127,128,131,136,137 A major diagnostic fea-
ture of IMN is the absence of findings to suggest reduction
or diversion of arterial flow. Another confounding factor
delaying recognition is the high incidence of diabetic neu-
ropathy in this population.129,130,131,136 When the clinical
neurologic examination is equivocal, electrodiagnostic
studies may facilitate diagnosis.
A deep, burning discomfort in the hand (or foot)
dominates the sensorimotor features of IMN that is con-
tinuous and persists for months. Sensory impairment is
most prominent distally, with pain, paresthesias, and
numbness in the distribution of all three forearm
nerves.124,129,131,137,142 Sensory symptoms are usually
more prominent than the physical findings, misleading the
clinician to consider a psychogenic or radiculopathic
etiology.142
The motor features include weakness or paralysis of the
muscles innervated by the three forearm nerves: radial
(wrist and finger extension), ulnar (abduction and adduc-tion of extended fingers), and median (thumb opposition,
flexion, abduction). The thumb is unable to oppose the
fingers (pinch). The end result is a claw-hand deformity
with profound loss of function and severe neuropathic
pain.137
Pathophysiology and electrodiagnostic studies. Wil-
bourn et al142 described multiple axonal-loss mononeu-
ropathies that developed abruptly, simultaneously, and
without evident muscle necrosis. In one of their three
patients, IMN developed as a consequence of an autoge-
nous AV access constructed for hemodialysis, and in the
others, IMN was related to arterial ischemia that was usu-
ally corrected by the time the neurologic symptoms were
recognized. In two of three patients in the Kaku et al143
report, IMN was access related. Subsequent reports have
focused on IMN encountered in hemoaccess patients. The
major risk factors (brachial arterial inflow, diabetes, and
usually female gender) are essentially those associated with
arterial steal syndrome.50,53,72,125,127-132,136
It is hypothesized that IMN results from transient or
localized diversion of the blood supply to the nerve trunk.
Evidence from animal and human studies supports the
selective loss of flow through the vasa nervorum.165,166
Thus, although arterial flow diversionmay be transient with
minimal evidence of persisting ischemia, the sensitivity of
neural tissue to ischemia (even though transient) may ren-
der it at greater risk for prolonged or permanent injury.
IMN thus most likely represents the residual effects of a
severe but subsequently collateralized arterial steal syn-
drome, with its effects manifested in the peripheral nerves.
Bolton et al124 described restoration of radial pulses,
but no neurologic improvement, when flow was reduced 6
weeks after construction of the AV access. In the AV access
patient reported by Wilbourn et al,142 a radial pulse was
absent for 11 days before autogenous AV access ligation
and 3 weeks before neurologic consultation. In clinical
practice and in the sparse literature on this topic, the
identification of arterial flow disturbances are not clearly
distinguished. Thus, IMN may be more simply conceived
as a particularly severe, focal neurologic consequence of
arterial steal syndrome and treated accordingly.
“EMG [electromyography] findings are suggestive of
axon-loss lesions of motor and sensory nerves supplying the
distal portion of one limb.”142 Reduced amplitudes of
nerve conduction are observed in the forearm and hand,
with the greatest reduction in the sensory fibers. Denerva-
tion is more severe distally, and the needle examination
gradually reverts to normal as one progresses proximally,
suggesting there is not a single site of infarction of a
proximal nerve trunk.142 Large and small axonal injury is
present without predilection for one size.142 Electrodiag-
nostic studies have been advocated to clarify the differential
diagnosis.127,128,131,143
Recommendations. Recognition of IMN is difficult
because it occurs so infrequently. A delay in diagnosis is
common and may compromise outcome.128,131,136,142 The
symptoms are commonly attributed to anesthesia (such as
axillary block), positioning, or surgical trauma.131,136 The
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artificial. Limbs manifesting clinical symptoms of IMN
should be managed aggressively in the presence or absence
of hemodynamic steal.
Recognition of IMN is the indication for deconstruc-
tion or revision of the AV access. IMN is best managed with
immediate sacrifice of the AV access or rerouting of arterial
inflow as described in the previous section on arterial steal
syndrome.3,128,131,136,137 The KDOQI Clinical Practice
Guideline 5.6.2 recommends emergency vascular access
surgical consultation for these symptoms.2
Peripheral nerve compression syndromes
Peripheral nerve compression syndromes in the chronic
hemodialysis patient may be amenable to surgical interven-
tion. The most common of these is median nerve compres-
sion at the wrist from carpal tunnel syndrome; less fre-
quently encountered is ulnar nerve compression in the
cubital or ulnar canal. The differential diagnosis is compli-
cated by the high incidence of concomitant uremic or
diabetic polyneuropathy. Outcome is compromised by de-
layed recognition and treatment.
Clinical features of median nerve entrapment (car-
pal tunnel). Median nerve compression in hemodialysis
patients was reported 10 years of the introduction of the
autogenous AV access.71,167 Clinical features of median
nerve entrapment consist of pain, numbness, and tingling
in the median nerve distribution to the palm. The pain
component is often greatest in the nocturnal hours and
usually worsens during dialysis.168-172 Atrophy and weak-
ness of the thenar muscles are clinically manifest as inability
to pinch between the thumb and index finger; motor
dysfunction is a late but more specific finding and suggests
a less complete or prolonged recovery. Even in nonrenal
populations, clinical diagnosis is difficult.173,174 In the
general population without renal failure, approximately
15% of patients offer appropriate complaints, but only 2%
to 3% are confirmed to have median nerve entrapment.173
Diagnosis and treatment decisions are often made on a
clinical basis alone; however, electrodiagnostic studies are
the most accurate adjunctive test despite recognized false-
negative and false-positive results.173,174 They are parti-
cularly useful when symptoms are suggestive—but not
classic—and coexisting neuropathy is present.
Substantive differences probably exist between median
nerve compression in the population at large and that on
hemodialysis. A 10-fold increase in incidence occurs, the
nondominant hand is more often symptomatic, male gen-
der is more predominant, outcomes are less complete, and
postoperative recurrence is a real issue.167,168,172 Although
compression neuropathy may occur earlier, symptoms are
most frequently manifest after 6 to 8 years on hemodialy-
sis.175,176 The probability increases with the length of time
on dialysis; for example, compression neuropathy was diag-
nosed in 35% of individuals who have received 5 years
of hemodialysis compared with 10% of those on dialysis5
years.168,169 The probability is60% if the patient has been
on dialysis for 10 years. If neuropathy was alreadypresent, the incidence was 59% at 5 years; overall, 31% of a
hemodialysis population had findings of carpal tunnel
syndrome.168
The differential diagnosis is significantly less distinct in
the ESRD patient, and even well-trained examiners have
had difficulty distinguishing nerve compression symptoms
from diffuse systemic neuropathy and arthropathy.171 As
might be expected, the incidence of entrapment neuropa-
thy is higher when electrodiagnostic studies are used for the
diagnosis.168,175,176
Enlargement and calcification of the median artery,
which accompanies the median nerve through the carpal
tunnel into the palm, is an unusual etiology of carpal tunnel
syndrome.177,178 Diffuse calcification of the media results
in enlargement of the external diameter of the artery that
exceeds a critical threshold in this unyielding restricted
space. The diagnosis may be suspected on review of plain
hand films when the bony structure is assessed for osteoar-
thropathy.177 Resection of the enlarged calcified median
artery is preferred; however, if a tourniquet is used, it must
be released to assess whether median artery resection results
in circulatory compromise to the hand.177,178 If the artery
is thrombosed, resection is uncomplicated; however, dis-
section and reimplantation may be required if it is the sole
blood supply to the index or middle fingers.178
Clinical features of ulnar nerve entrapment (cubital
and ulnar tunnels). Ulnar nerve entrapment neuropathy has
also been reported in hemodialysis patients.168,170,171,179-181
The clinical features of ulnar nerve entrapment include pain,
paresthesia, and sensory loss to the ulnar aspect of the fourth and
theentirefifthdigit;weaknessof thedorsal andvolar interosseous
muscles (abduction and adduction of the extended digits) and
hypothenar muscles (atrophy and weakness of forceful grasp-
ing).168,179 Compression of the ulnar nerve in the ulnar
tunnel at the wrist (Guyon’s syndrome) is characterized
by a similar distribution of symptoms. The cubital and
ulnar tunnels are both managed by decompression. Al-
though entrapment is usually considered as a monone-
uropathy, median and ulnar entrapment may occur
together—a difficult diagnosis indeed.168,170,179,180,181
Role of electrodiagnostic studies. Electrodiagnostic
studies may include ulnar, median, and peroneal nerve
conduction studies and electromyography; two abnormal
nerves in a single extremity or symmetrical dysfunction
suggest a diagnosis of polyneuropathy.168,171,173-175 How-
ever, results of electromyography and nerve conduction
studies are abnormal in many more patients than those
exhibiting clinical findings. When the diagnosis is based on
electrodiagnostic studies, peripheral nerve dysfunction is
identified with equal frequency in the extremity contralat-
eral to the AV access.175,176 Some authors have recom-
mended annual lower extremity electrodiagnostic studies
because the role of entrapment is obfuscated by the fre-
quency of coexistent polyneuropathy.171,175 Although ear-
lier KDOQI guidelines specifically state that there is
compelling indication for electrodiagnostic studies in
asymptomatic patients, most hemodialysis patients do have
some peripheral symptoms.182 Delay in diagnosis is com-
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to both steal syndrome and coexisting neuropathy.
Although entrapment neuropathy is often assumed to
be directly related to the access, this cannot be clearly
discerned from the available data. Some reports have sug-
gested that the equivalency of electrodiagnostic study find-
ings in both upper extremities is evidence against
this.168,171,175 The occurrence of carpal tunnel syndrome
in patients with chronic peritoneal dialysis also suggests
that a systemic pathophysiology underlies carpal tunnel
syndrome.175,183,184
Pathophysiology: compartment pressures and -
amyloid. Localized pressure elevation within the carpal
tunnel is considered the primary pathophysiologic mecha-
nism.169,173,185 Normal pressures are 2.5 mm Hg in the
neutral, relaxed position and rise to 30 to 31 mm Hg with
flexion and extension.185 The complete elimination of elec-
trodiagnostic impulses when tissue pressure thresholds
reached a critical value of 40 to 50 mm Hg suggest that
localized neural ischemia is responsible for entrapment
neuropathy; Semmes-Weinstein filaments and 256 cps vi-
bratory stimulus were also found to correlate more closely
with electrodiagnostic study findings than the traditional,
widely accepted 2-point discrimination.186 Abnormal,
chronically elevated pressures in the carpal tunnel (24
and 32 mm Hg) were documented intraoperatively in
patients with the clinical diagnosis of carpal tunnel
syndrome.169,185 Accumulation of -amyloid is one postu-
lated etiology that is consistent with the 6- to 8-year latency
for development of compression neuropathies. Thickening
of connective tissues is attributed to deposition of amyloid
in the form of serum 2-microglobulin.
171,181 This protein
is normally found in the walls of leukocytes and is excreted
by the kidneys; it accumulates in periarticular structures and
is also associated with osteodystrophy and crippling arthro-
pathy.169,187
Management: release of median or ulnar entrap-
ment; tourniquet. In patients without renal failure, mild
symptoms of median or ulnar nerve entrapment are initially
managed with splints, anti-inflammatory medication, and
corticosteroid injection.171,173 Surgical decompression of
the median nerve consists of transection of the transverse
carpal ligament, which may be done as an open or endo-
scopic procedure. Although a reduction in the duration of
pain from the scar was demonstrated with the endoscopic
procedure, a randomized trial demonstrated no other dif-
ferences between the two techniques, including return to
work.188
Ulnar nerve entrapment is relieved by surgical decom-
pression of the cubital or ulnar tunnels. Surgical interven-
tion is recommended for symptoms suggestive of axonal
loss, such as persistent numbness, symptoms 1 year,
weakness, or muscular atrophy.173 It has been repeatedly
emphasized that early recognition and treatment is associ-
ated with improved outcomes.168,169
Vascular surgeons may be asked to approve use of a
tourniquet for release of the flexor retinaculum. Although
one author reported no autogenous AV access loss whentourniquet times were 45 minutes, the tourniquet was
not advocated for prosthetic AV accesses.169 However, two
of 14 autogenous AV accesses thrombosed in another
report.170 If recognized after release of the tourniquet,
revision and thrombectomy may be performed while in the
operating room.170 The procedure itself is quite rapid, but
surgical consultants will have to determine whether the risk
of thrombosis justifies adjunctive use of the tourniquet on
an individual basis. When the use of a tourniquet on the
arm bearing the AV access is being considered, a preproce-
dural duplex ultrasound examination should be obtained to
determine whether the AV access is at risk due to stenoses
or reduced flow.
Results of treatment. Patients in the general popula-
tion with median nerve decompression experience pain
relief immediately. More than 70% reported complete sat-
isfaction with surgical treatment, but return of muscular
strength was usually delayed for months.173 The results
with AV access patients are less satisfying but follow a
similar sensory-to-motor progression.168,189 Prolonged
symptoms may not respond, particularly when weakness
and atrophy are advanced.169,171,172 A “good” result was
reported in 76%; those with preoperative symptoms for2
years improved the least, recovering some sensation but
little motor function.169 A more detailed assessment de-
scribed “good” relief of pain in 81%, relief of paresthesia in
51%, and improvement of grip strength of 8%.172 Carpal
tunnel syndrome is particularly disabling for those perform-
ing self-dialysis, in whom compression release restored this
capability.167
Because almost all ESRD patients have some evidence
of polyneuropathy, the symptoms suggesting entrapment
will tend to be more advanced at the time of presentation;
this combined with the difficulty of diagnosis and separa-
tion of symptoms between entrapment and other neurop-
athies may explain these disparate results. Despite this, once
recognized, release of entrapped neural trunks is appropri-
ate, with the caveat that those with motor findings or
prolonged untreated symptomatic nerve compression will
fare less well. The role of splints or injections has not been
well addressed in the hemodialysis patient.
Unlike carpal tunnel syndrome in the general popula-
tion, repeat surgical decompression is occasionally neces-
sary for recurrent symptoms. Unfortunately, the result of
repeat surgical release is less encouraging; even pain was not
always relieved, and the duration of improvement was
decreased.170-172 The incidence of recurrent carpal tunnel
syndrome varies with the institution but may be as high as
19% in a given hemodialysis population.172
Recommendations. Entrapment neuropathy results
in significant disability. The clinical distinction between
median or ulnar nerve compression syndromes, steal, and
polyneuropathy is often not easy. Ulnar compression syn-
dromes are less commonly recognized, may occur in con-
junction with carpal tunnel syndrome, and make differen-
tial diagnosis more difficult. Surgical decompression is a
rapid, well-tolerated procedure that usually results in im-
mediate pain relief. However, when motor dysfunction is
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pletely, particularly if compression symptoms have been
present for a prolonged time or when there is pre-existing
neuropathy. Electrodiagnostic studies may identify a focal
nerve dysfunction but have not been a good predictor of
success from release of the compression.170,174
Polyneuropathy: uremic and diabetic
Complicating the assessment of surgically treatable
neuropathy is the high incidence of diffuse polyneuropathy
in patients with advanced chronic renal failure. Fully
50% to 70% of patients with ESRD will have polyneurop-
athy.183,190,191 More than 60% of diabetic patients will
have some form of neuropathy, the most common of which
is polyneuropathy.192 The combination of diabetes and
chronic uremia may be expressed as a more acute or more
severe form of polyneuropathy.193-195
Clinical features of uremic neuropathy. The clinical
and histopathologic findings of uremic neuropathy were
recognized and described just before widespread applica-
tion of transplantation or hemodialysis.196 Before the ad-
vent of modern renal replacement therapy, insoluble met-
abolic abnormalities and coma generally dominated the
care of the patient in terminal renal failure. As survival
lengthened with dialysis therapy, these findings became
more prevalent and the adverse effect on quality of life more
apparent. Symptoms from uremic neuropathy are rare until
the GFR is 12 to 20 mL/min (class 5 chronic renal
failure).183,189
The typical clinical findings usually begin in the lower
extremity, but eventually may involve all four extremi-
ties.189,196 Symptoms initially manifest as a burning pain in
the sole of the foot with sensations of numbness or tingling;
this is followed by loss of peripheral reflexes and vibration
sense. The earliest motor complaint is usually weakness of
ankle or toe dorsiflexion.189 Symptomatic uremic polyneu-
ropathy develops insidiously in most individuals; however,
occasionally it will develop in a fulminant acute form.197
Consistent with the systemic nature of uremic polyneurop-
athy, autonomic fibers are involved but usually produce
minimal, clinically insignificant symptoms.191
Pathophysiology and electrodiagnostic studies. The
typical clinical findings result from axonal degeneration,
with a particular predilection for large-diameter axons in
the most distal nerve trunks of the extremities.189,196-198
Distal segmental demyelination and axonal degeneration
have been confirmed, but the mechanism remains un-
known.189,191,197 Although frequently asymptomatic,
slowing of sensory nerve conduction is the earliest neuro-
physiologic abnormality.183
Results of treatment. The symptoms of uremic poly-
neuropathy are rarely reversed by dialysis; occasionally they
become worse, but the usual outcome is stabilization.
Attempts to alter the progression with dietary therapy or
manipulation of the mechanics and scheduling of dialysis,
or both, have no effect in reversing uremic neuropathic
symptoms.191,199 In contrast, the symptoms are often dra-
matically reversed after renal transplantation.189,191,198 Af-ter successful renal transplantation, reversal of wasting and
weakness occur more slowly, with deep tendon reflexes
recovering last during 9 to 12 months.189
Other neurologic abnormalities (ie, dementia, disequi-
librium syndrome, Wernicke’s encephalopathy, etc) that
may be seen in patients with renal insufficiency are beyond
the scope of this review.189
Clinical features of diabetic neuropathy. Diabetic
polyneuropathy has been recognized in many forms and is
generally thought to be the most common etiology of
polyneuropathy. Mononeuropathy and autonomic dys-
function occurs in 50% to 60% of diabetic patients.192 The
incidence increases with the duration of diabetes.192 Sev-
eral forms are known. The most prevalent manifestation is a
distal, symmetrical, sensory neuropathy, often described as
having a stocking or glove distribution; the more debilitat-
ing form consists of burning or lancinating pain. It usually
develops insidiously, continues to progress, and rarely im-
proves. Sensory and autonomic findings are more promi-
nent thanmotor impairment.200 Cranial nerve involvement
most commonly affects the muscular innervation of ocular
movement and will frequently improve on its own. The
more central neuropathies are more likely to resolve and
return to normal. Unlike the uremic form, diabetic auto-
nomic neuropathy is likely to be symptomatic and is man-
ifested as gastroparesis, impotence, nocturnal diarrhea, loss
of sphincter control, or postural hypotension192,194; this
too has a low expectation for improvement.
In a prospective, population based cohort, Dyck
et al192 performed a longitudinal study using standardized
and validated assessments of the type and stages of poly-
neuropathy. When evaluated by sensitive and comprehen-
sive diagnostic methods, the incidence of neuropathy
was 66% in insulin-dependent diabetes mellitus (IDDM)
and 59% in noninsulin-dependent diabetes mellitus
(NIDDM).192 The most common type was a polyneurop-
athy in 45% to 54% and visceral autonomic neuropathy in
5% to 7%.However, symptomatic neuropathy was observed
in only 15% patients with IDDM and 13% with NIDDM.
Severe neuropathic symptoms were significantly more com-
mon in those with IDDM (6% vs 1%). Interestingly, 10% of
neurologic symptoms were not of diabetic etiology, and 7%
had symptomatic carpal tunnel syndrome.192
Pathophysiology and electrodiagnostic studies. De-
spite its prevalence, the etiology of diabetic polyneuropathy
remains unknown.200 Suggested etiologies include meta-
bolic abnormalities, local hypoxia, thickened basement
membranes, or perivascular inflammation.200,201 The
range of histologic findings include axonal degeneration,
segmental demyelination, remyelination, and hypertrophy
of basal lamina.194 In the fulminant acute form, this may
advance at the rate of a few hundred micrometers per
day.194 Dying back fibers are a characteristic of centripetal
degeneration of peripheral axons. Mild slowing of motor
and sensory conduction is a common finding in the diabetic
patient, with or without diabetic symptoms; more severe
symptoms are associated with further decreases or absence
of conduction.192
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developed, there is rarely a specific remedy. Level I data
have demonstrated that tightly controlled glucose moni-
toring reduces the likelihood of developing neuropathy in
IDDM.202 The effect of pancreatic transplantation on dia-
betic neuropathy has not been clarified; however, one
long-term study observed continued, slow improvement in
neurophysiology in patients observed for up to 10 years.203
Recommendations: uremic and diabetic neuropa-
thy. Symmetrical distal sensory findings are common to
both uremic and diabetic etiologies. Acute onset and rapid
progression of severe neuropathy has been reported for
both diabetic and uremic etiologies.193-195 When both
occur together, however, functional deterioration can be
accelerated even further. Beginning with the typical distal
sensory dysfunction, this formmay progress within months
or years, leaving patients with an inability to stand or
walk.193,195
The clinical effects of uremic or diabetic peripheral
polyneuropathy are essentially indistinguishable; however,
symptomatic autonomic neuropathy is more likely to result
from diabetes. The severity of the typical distal, symmetrical
sensory neuropathy correlates with the duration of the
diabetes and with the duration of dialysis-dependent
chronic renal failure. Diabetic patients who require dialysis
are subject to greater severity of clinical symptomatology.
Recognition of uremic or diabetic polyneuropathy con-
founds the recognition and may delay intervention of sur-
gically amenable compression or ischemic neuropathy.
Electrodiagnostic studies may help to distinguish these
etiologies in symptomatic patients.
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